[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Nova Biomedical Corporation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":157},{"warningLetters":4,"total":156},[5,32,55,76,96,114,135],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},534,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-10-21T04:00:00Z\">10\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-09T04:00:00Z\">10\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmelcare-biomedical-pty-ltd-717968-10092025\">Melcare Biomedical Pty Ltd\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Anthony Moloney\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Group CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Melcare Biomedical Pty Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>451 West Mount Cotton Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mount Cotton\u003C\u002Fspan> \u003Cspan>QLD\u003C\u002Fspan> \u003Cspan>4165\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Australia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:anthonym@melcare.com\"> anthonym@melcare.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 9, 2025\u003C\u002Fp>\u003Cp>RE: 717968\u003C\u002Fp>\u003Cp>Dear Mr. Moloney:\u003C\u002Fp>\u003Cp>This letter is to advise you that on September 10, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address melcare.com where your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products are available for purchase in the United States without a prescription. We also reviewed your social media site on YouTube https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=W0nofWh_uGU&amp;t=12s, which is listed on your website.\u003C\u002Fp>\u003Cp>Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cu>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims from the Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops labeling, including on your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Optimel Manuka+ Forte Eye Gel\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“DRUG FACTS…USES…▪for the temporary relief of irritation due to dryness of the eye. ▪ for use as a protectant against further irritation or to relive dryness of the eye.” [from the Drug Facts panel on product carton labeling]\u003C\u002Fp>\u003Cp>“Suitable For: ▪Aqueous tear deficiency ▪ eye discomfort ▪ eye lid irritation [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\u003C\u002Fp>\u003Cp>“Melcare’s Optimel Manuka+ Forte Eye Gel contains a standardised [sic] medical grade Manuka honey developed from \u003Cem>Leptospermum\u003C\u002Fem> spp. and is preservative free for moderate to severe dry eye” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\u003C\u002Fp>\u003Cp>“Albietz and Lenton also reported that the application of medical grade \u003Cem>Leptospermum\u003C\u002Fem> spp honey (Manuka) was associated with signficant [sic] clinical improvements in dry eye and meibomian gland dysfunction” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\u003C\u002Fp>\u003Cp>“Indications…Optimel Manuka+ Forte Eye Gel containing 98% honey with increased viscosity is preservative free, and is also available for more difficult conditions from your eye care specialist.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Optimel Manuka+ Dry Eye Drops\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“DRUG FACTS…USES… ▪for the temporary relief of irritation due to the dryness of the eye. ▪ for use as a protectant against further irritation or to relieve dryness of the eye.” [from the Drug Facts panel on product carton labeling]\u003C\u002Fp>\u003Cp>“Suitable For: ▪Chronic dry eye ▪ Eye discomfort ▪ Sore, irritated eyes and eyelids” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\u003C\u002Fp>\u003Cp>“About the Product…Albietz and Lenton also reported that the application of medical grade \u003Cem>Leptospermum\u003C\u002Fem> spp honey (Manuka) was associated with signficant [sic] clinical improvements in dry eye and meibomian gland dysfunction.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Multiple products\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“At Melcare, we are experts in the therapeutic use of honey in products to help relieve some of the symptoms associated with chronic disease. Honeys from Australian and New Zealand \u003Cem>Leptospermum\u003C\u002Fem> spp, commonly called Manuka, a small native tree is favoured because of its well-studied composition and antibacterial activity.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fabout-us\u002F]\u003C\u002Fp>\u003Cp>YouTube video posted on your website created on June 18, 2020 that includes statements by Melcare’s President, Anthony Maloney, emphasizes the use of honey and it’s benefits in drug products. For example, Mr. Maloney states in the video, “We developed a range of products that use and leverage off the therapeutic efficacy of honey that is in wound care, eye care, skin care, and throat care.” [from your YouTube video on your product website at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=W0nofWh_uGU&amp;t=12s]\u003C\u002Fp>\u003Cp>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are intended for use as ophthalmic demulcent (lubricant) drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for any of the product identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops, in order to be GRASE and not new drugs, these products must, among other things, conform to the conditions in the applicable OTC monograph, here OTC monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products do not conform to the conditions specified in M018 for the reasons described below, and thus cannot be legally marketed under section 505G.\u003C\u002Fp>\u003Cp>Specifically, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products are formulated with honey (from \u003Cem>Leptospermum\u003C\u002Fem> spp.). Although you identify honey as an inactive ingredient on the product label, statements on your website show that honey is presented as an active ingredient, because it is intended to furnish pharmacological activity for the treatment of a disease or condition.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, honey is not an active ingredient permitted for OTC monograph ophthalmic demulcent drug products under M018.12. Examples of you labeling statements presenting honey as an active ingredient include, “Optimel Manuka+ Forte Eye Gel contains a standardised medical grade Manuka honey developed from \u003Cem>Leptospermum\u003C\u002Fem> spp. and is preservative free for moderate to severe dry eye,” “The application of medical grade \u003Cem>Leptospermum\u003C\u002Fem> spp honey (Manuka) was associated with significant clinical improvements in dry eye and meibomian gland dysfunction,” and “We are experts in the therapeutic use of honey in products to help relieve some of the symptoms associated with chronic disease.” Additionally, a YouTube video created on June 18, 2020 and posted on your website includes statements by Melcare’s President, Anthony Maloney, describing the medical benefits of honey. For example, Mr. Maloney states, “We developed a range of products that use and leverage off the therapeutic efficacy of honey that is in wound care, eye care, skin care, and throat care.” Thus, honey is used in your product as an active ingredient and, because it is not an active ingredient permitted under M018.12, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products do not conform with the conditions for lawful marketing of an OTC ophthalmic demulcent or vasoconstrictor drug product as set forth in M018.\u003C\u002Fp>\u003Cp>Therefore, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products do not comply with the applicable conditions specified in M018. In addition, these products have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov . Please include your firm name and the unique identifier 717968 in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M018 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3 \u003C\u002Fstrong>\u003C\u002Fem>FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products are GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nAnthony Moloney\n\nRecipient Title\n\nGroup CEO\n\nMelcare Biomedical Pty Ltd\n\n451 West Mount Cotton Rd\n\nMount Cotton QLD 4165\n\nAustralia\n\nanthonym@melcare.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nOctober 9, 2025\nRE: 717968\nDear Mr. Moloney:\nThis letter is to advise you that on September 10, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address melcare.com where your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products are available for purchase in the United States without a prescription. We also reviewed your social media site on YouTube https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=W0nofWh_uGU&t=12s, which is listed on your website.\nOptimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\nOptimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples of claims from the Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops labeling, including on your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nOptimel Manuka+ Forte Eye Gel\n“DRUG FACTS…USES…▪for the temporary relief of irritation due to dryness of the eye. ▪ for use as a protectant against further irritation or to relive dryness of the eye.” [from the Drug Facts panel on product carton labeling]\n“Suitable For: ▪Aqueous tear deficiency ▪ eye discomfort ▪ eye lid irritation [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\n“Melcare’s Optimel Manuka+ Forte Eye Gel contains a standardised [sic] medical grade Manuka honey developed from Leptospermum spp. and is preservative free for moderate to severe dry eye” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\n“Albietz and Lenton also reported that the application of medical grade Leptospermum spp honey (Manuka) was associated with signficant [sic] clinical improvements in dry eye and meibomian gland dysfunction” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\n“Indications…Optimel Manuka+ Forte Eye Gel containing 98% honey with increased viscosity is preservative free, and is also available for more difficult conditions from your eye care specialist.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\nOptimel Manuka+ Dry Eye Drops\n“DRUG FACTS…USES… ▪for the temporary relief of irritation due to the dryness of the eye. ▪ for use as a protectant against further irritation or to relieve dryness of the eye.” [from the Drug Facts panel on product carton labeling]\n“Suitable For: ▪Chronic dry eye ▪ Eye discomfort ▪ Sore, irritated eyes and eyelids” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\n“About the Product…Albietz and Lenton also reported that the application of medical grade Leptospermum spp honey (Manuka) was associated with signficant [sic] clinical improvements in dry eye and meibomian gland dysfunction.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\nMultiple products\n“At Melcare, we are experts in the therapeutic use of honey in products to help relieve some of the symptoms associated with chronic disease. Honeys from Australian and New Zealand Leptospermum spp, commonly called Manuka, a small native tree is favoured because of its well-studied composition and antibacterial activity.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fabout-us\u002F]\nYouTube video posted on your website created on June 18, 2020 that includes statements by Melcare’s President, Anthony Maloney, emphasizes the use of honey and it’s benefits in drug products. For example, Mr. Maloney states in the video, “We developed a range of products that use and leverage off the therapeutic efficacy of honey that is in wound care, eye care, skin care, and throat care.” [from your YouTube video on your product website at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=W0nofWh_uGU&t=12s]\nUnapproved New Drug Violations\nBased on the above labeling evidence, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are intended for use as ophthalmic demulcent (lubricant) drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for any of the product identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops, in order to be GRASE and not new drugs, these products must, among other things, conform to the conditions in the applicable OTC monograph, here OTC monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).1 However, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products do not conform to the conditions specified in M018 for the reasons described below, and thus cannot be legally marketed under section 505G.\nSpecifically, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products are formulated with honey (from Leptospermum spp.). Although you identify honey as an inactive ingredient on the product label, statements on your website show that honey is presented as an active ingredient, because it is intended to furnish pharmacological activity for the treatment of a disease or condition.2 However, honey is not an active ingredient permitted for OTC monograph ophthalmic demulcent drug products under M018.12. Examples of you labeling statements presenting honey as an active ingredient include, “Optimel Manuka+ Forte Eye Gel contains a standardised medical grade Manuka honey developed from Leptospermum spp. and is preservative free for moderate to severe dry eye,” “The application of medical grade Leptospermum spp honey (Manuka) was associated with significant clinical improvements in dry eye and meibomian gland dysfunction,” and “We are experts in the therapeutic use of honey in products to help relieve some of the symptoms associated with chronic disease.” Additionally, a YouTube video created on June 18, 2020 and posted on your website includes statements by Melcare’s President, Anthony Maloney, describing the medical benefits of honey. For example, Mr. Maloney states, “We developed a range of products that use and leverage off the therapeutic efficacy of honey that is in wound care, eye care, skin care, and throat care.” Thus, honey is used in your product as an active ingredient and, because it is not an active ingredient permitted under M018.12, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products do not conform with the conditions for lawful marketing of an OTC ophthalmic demulcent or vasoconstrictor drug product as set forth in M018.\nTherefore, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products do not comply with the applicable conditions specified in M018. In addition, these products have not otherwise been found GRASE.3 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov . Please include your firm name and the unique identifier 717968 in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nCc: (b)(4)\n__________________\n1 M018 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n2 See21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products are GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).","Melcare Biomedical Pty Ltd","melcare-biomedical-pty-ltd-717968-10092025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmelcare-biomedical-pty-ltd-717968-10092025","2026-10-26T08:09:23.825007+00:00","Warning Letter","Issued","2025-10-21","717968","Drugs Over-the-Counter Drugs","Anthony Moloney","2026-08-19T16:13:40.714+00:00","Via Email","2025-10-09",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":24,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":20,"issuing_office":38,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":20,"reference_number":20,"action_taken_date":54,"medical_device_id":20,"response_letter_date":20},2638,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2022-05-31T13:20:00Z\">05\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-31T04:00:00Z\">03\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fosteolife-biomedical-i-llc-626889-03312022\">OsteoLife Biomedical I LLC\u003C\u002Fa>","Office of Biological Products Operations – Division I","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Theodore I. Malinin, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Medical Director and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>OsteoLife Biomedical I LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1951 NW 7th Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sanibel Suite\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33136\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 31, 2022\u003C\u002Fp>\n\n\u003Cp>22-626889\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Malinin:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, OsteoLife Biomedical I LLC, located at 1951 NW 7th Avenue, Sanibel Suite, Miami, FL, between December 6, 2021 and February 4, 2022. During the inspection, an FDA investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 [21 CFR 1271] and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\u003C\u002Fp>\n\n\u003Cp>The deviations documented on the Form FDA-483, List of Inspectional Observations (Form FDA-483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1) Failure to process HCT\u002FPs in a way that does not cause contamination or cross-contamination during processing and that prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP [21 CFR 1271.220(a)]. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Your establishment processes multiple batches of Freeze-Dried Particulate Bone from a single donor on the same day, by the same processing technician, under the same environmental conditions, and using the same equipment. Cleaning of equipment and facilities is not performed in \u003Cstrong>(b)(4)\u003C\u002Fstrong> each batch. Post-processing cultures of vials from one or more batches from a single donor tested positive for microorganisms, several of which were identified on multiple occasions. Although positive microbiological cultures were found in some batches, other batches from the same donor were distributed. For example:\u003C\u002Fp>\n\n\u003Cp>i. On November 16, 2021, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Freeze-Dried Particulate Bone were manufactured from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong>. A post-processing culture was positive for \u003Cem>Bacillus\u003C\u002Fem> (not \u003Cem>anthracis\u003C\u002Fem>) in one batch manufactured from this donor.\u003C\u002Fp>\n\n\u003Cp>ii. On July 7, 2021, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Freeze-Dried Particulate Bone were manufactured from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong>. Post-processing cultures were positive for \u003Cem>Stenotrophomonas maltophilia\u003C\u002Fem> in two batches manufactured from this donor.\u003C\u002Fp>\n\n\u003Cp>iii. On May 13, 2021, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Freeze-Dried Particulate Bone were manufactured from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong>. Post-processing cultures were positive for \u003Cem>Stenotrophomonas maltophilia\u003C\u002Fem> or \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> in four batches manufactured from this donor.\u003C\u002Fp>\n\n\u003Cp>iv. On April 30, 2020, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Freeze-Dried Particulate Bone were manufactured from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong>. A post-processing culture was positive for \u003Cem>Micrococcus luteus\u003C\u002Fem> in one batch manufactured from this donor.\u003C\u002Fp>\n\n\u003Cp>b. During the inspection, the FDA investigator observed processing of HCT\u002FPs, from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on December 28, 2021, that significantly increased the potential for contamination and did not prevent the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FPs. Specifically, the investigator noted the high velocity return air slots of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Laminar Flow Bench, located along the front edge of the work surface and that provide protection from a “backwash” of dirty air into the work area, were covered with a sterile sheet\u002Fdrape.\u003C\u002Fp>\n\n\u003Cp>2) Failure to validate and approve processes according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests [21 CFR 1271.230(a)]. For example:\u003C\u002Fp>\n\n\u003Cp>You failed to adequately validate the manufacturing process for the Flexo-Plate, and Flexo-Membrane, and Freeze-Dried Particulate Bone products. Your “Processing of Flexo-plate and Membrane Grafts Process Qualification Summary Report” (dated October 14, 2019) and “Processing of Particulate Tissue Process Qualification Summary Report” (dated October 4, 2019) fail to include in-process microbiological testing to ensure that you are not introducing contamination during processing and that your process removes any contamination present. In addition, the documents noted above do not include any acceptance criteria related to microbiological contamination of HCT\u002FPs or the types of microorganisms typically encountered on such HCT\u002FPs.\u003C\u002Fp>\n\n\u003Cp>3) Failure to monitor environmental conditions where they could reasonably be expected to cause contamination or cross contamination of HCT\u002FPs or equipment, or accidental exposure of HCT\u002FPs to communicable disease agents [21 CFR 1271.195(c)]. For example:\u003C\u002Fp>\n\n\u003Cp>Your January 2020 through November 2021 processing session logs indicate that you conduct environmental monitoring for microorganisms approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you do not perform environmental monitoring during processing. The introduction, transmission, or spread of communicable diseases could reasonably be expected to occur during processing, therefore, you would be expected to perform environmental monitoring for microorganisms during processing.\u003C\u002Fp>\n\n\u003Cp>4) Failure to investigate HCT\u002FP deviations and trends of HCT\u002FP deviations relating to core CGTP requirements. Under the applicable regulation, each investigation must include a review and evaluation of the HCT\u002FP deviation, the efforts made to determine the cause, and the implementation of corrective action(s) to address the HCT\u002FP deviation and prevent recurrence [21 CFR 1271.160(b)(6)]. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. After the issuance of an Untitled Letter dated July 22, 2019, you submitted an initial HCT\u002FP deviation report to FDA on September 17, 2019, regarding the distribution of HCT\u002FPs after receipt of positive post-processing cultures. You submitted supplemental information on November 1, 2019, and April 14, 2020. The deviation reports stated you performed an investigation and proposed the reason for the positive post-processing cultures as inadvertent contamination of the sample at the microbiology laboratory when the plastic pouch containing the sample was opened by the testing laboratory that performed the microbiological testing.\u003C\u002Fp>\n\n\u003Cp>As noted above, you continued to have positive post-processing cultures. You subsequently opened 22 investigations of positive post-processing cultures for bone products processed between April 2020 and December 2021; however, the investigations were closed and once again, you failed to identify corrective actions to address the ongoing deviations and to prevent their recurrence. For example:\u003C\u002Fp>\n\n\u003Cp>i. On May 24, 2021, post-processing cultures for Freeze-Dried Particulate Bone from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> tested positive for \u003Cem>Stenotrophomonas maltophilia\u003C\u002Fem> and \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem>. You opened “HCT\u002FP Deviation #005” after the initiation of the inspection and closed the investigation on December 7, 2021.\u003C\u002Fp>\n\n\u003Cp>ii. On May 8, 2020, post-processing cultures for Freeze-Dried Particulate Bone from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> tested positive for \u003Cem>Micrococcus luteus\u003C\u002Fem>. You opened “HCT\u002FP Deviation #001” after the initiation of the inspection and closed the investigation on December 7, 2021.\u003C\u002Fp>\n\n\u003Cp>b. Between January 2020 and November 2021, you performed environmental monitoring prior to cleaning your processing room, which resulted in 10 positive microbiological cultures from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, one positive microbiological culture from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for multiple processing steps to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and one positive microbiological culture from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Laminar Flow Bench. For example:\u003C\u002Fp>\n\n\u003Cp>i. On July 29, 2021, an environmental settling plate (S-072221-09235) from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> table tested positive for Fungi, and \u003Cem>Bacillus\u003C\u002Fem> species (not \u003Cem>anthracis\u003C\u002Fem>). You opened “HCT\u002FP Deviation #E002” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\u003C\u002Fp>\n\n\u003Cp>ii. On July 12, 2021, an environmental settling plate (S-070421-03649) from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Laminar Flow Bench tested positive for gram-positive cocci and \u003Cem>Staphylococcus petrasii\u003C\u002Fem>. You opened “HCT\u002FP Deviation #E001” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\u003C\u002Fp>\n\n\u003Cp>iii. On September 8, 2020, an environmental touch plate (S-090220-08144) from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tested positive for \u003Cem>Bacillus\u003C\u002Fem> species (not \u003Cem>anthracis\u003C\u002Fem>), coagulase-negative \u003Cem>Staphylococcus\u003C\u002Fem>, and \u003Cem>Bacillus marisflavi\u003C\u002Fem>. You opened “HCT\u002FP Deviation #E-006” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\u003C\u002Fp>\n\n\u003Cp>The deviations identified above are not intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure that your establishment is operating in compliance with all the applicable regulatory requirements. You are responsible for reviewing your firm’s operations as a whole to ensure that you fully comply with the law.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letter dated February 23, 2022, in response to the Form FDA-483, issued to your establishment at the close of the inspection. We have reviewed the corrective actions outlined in the response and we have the following comments:\u003C\u002Fp>\n\n\u003Cp>1. In your response to Observation 1, under paragraph 1(a), your revised SOP 110-006, Release of Processed Tissues states, “... in the event of a positive culture(s) the entire number of batches processed from the same donor during a processing session will be discarded.” Your response does not address your plan for the HCT\u002FPs you have already processed in violation of 21 CFR 1271 that have already been distributed, as well as the HCT\u002FPs that currently remain in storage.\u003C\u002Fp>\n\n\u003Cp>2. In response to Observation 2, under paragraph 2(b) you stated you would, “Revalidate entire process for Processing of Flexo-Plate &amp; Flexo-Membrane Grafts and Particulate Tissue.” We note that under 21 CFR 1271.230(a), process validation must be performed before manufacturing HCT\u002FPs. Your response does not indicate that you will halt processing of Flexo-Plate &amp; Flexo-Membrane Grafts and Particulate Tissue products until your processes have been validated.\u003C\u002Fp>\n\n\u003Cp>3. In response to Observations 4 and 5, you stated that “CAPA#002, Manufacturing monitoring to mitigate contamination” and “CAPA#003, Environmental monitoring” were initiated as corrective actions and that they would be completed by April 2022. Your changes will be reviewed during the next inspection of your establishment to confirm compliance with 21 CFR 1271.\u003C\u002Fp>\n\n\u003Cp>4. In response to Observation 6, you stated that CAPA #001, “Quality Program Continuous Improvement and Enforcement” was initiated that includes drafting a new SOP on how to perform investigations detailing root cause analysis to be completed by April 2022. Your changes will be reviewed during the next inspection of your establishment to confirm compliance with 21 CFR 1271.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your product is not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Given the seriousness of these violations, we also request your attendance at a Regulatory Meeting, within 30 calendar days of receipt of this letter, to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. We will host the meeting virtually on Zoom. This meeting will also allow you to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Colleen Aspinwall, Compliance Officer, at (561) 416-1065, ext. 1105 or by email at Colleen.Aspinwall@fda.hhs.gov for confirmation of the meeting date and time. A call-in phone number for the Zoom meeting will be provided at that time.\u003C\u002Fp>\n\n\u003Cp>Your response should be emailed to Colleen.Aspinwall@fda.hhs.gov. If you should have any questions, please contact Colleen Aspinwall, Compliance Officer, at (561) 416-1065, ext. 1105 or via email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division I\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nTheodore I. Malinin, MD\n\nRecipient Title\n\nMedical Director and Co-Owner\n\nOsteoLife Biomedical I LLC\n\n1951 NW 7th Avenue\n\nSanibel Suite\n\nMiami, FL 33136\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division I\n\nUnited States\n\nWARNING LETTER\n\nMarch 31, 2022\n\n22-626889\n\nDear Dr. Malinin:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, OsteoLife Biomedical I LLC, located at 1951 NW 7th Avenue, Sanibel Suite, Miami, FL, between December 6, 2021 and February 4, 2022. During the inspection, an FDA investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 [21 CFR 1271] and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\n\nThe deviations documented on the Form FDA-483, List of Inspectional Observations (Form FDA-483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\n\n1) Failure to process HCT\u002FPs in a way that does not cause contamination or cross-contamination during processing and that prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP [21 CFR 1271.220(a)]. Specifically:\n\na. Your establishment processes multiple batches of Freeze-Dried Particulate Bone from a single donor on the same day, by the same processing technician, under the same environmental conditions, and using the same equipment. Cleaning of equipment and facilities is not performed in (b)(4) each batch. Post-processing cultures of vials from one or more batches from a single donor tested positive for microorganisms, several of which were identified on multiple occasions. Although positive microbiological cultures were found in some batches, other batches from the same donor were distributed. For example:\n\ni. On November 16, 2021, (b)(4) batches of Freeze-Dried Particulate Bone were manufactured from donor (b)(6). A post-processing culture was positive for Bacillus (not anthracis) in one batch manufactured from this donor.\n\nii. On July 7, 2021, (b)(4) batches of Freeze-Dried Particulate Bone were manufactured from donor (b)(6). Post-processing cultures were positive for Stenotrophomonas maltophilia in two batches manufactured from this donor.\n\niii. On May 13, 2021, (b)(4) batches of Freeze-Dried Particulate Bone were manufactured from donor (b)(6). Post-processing cultures were positive for Stenotrophomonas maltophilia or Pseudomonas aeruginosa in four batches manufactured from this donor.\n\niv. On April 30, 2020, (b)(4) batches of Freeze-Dried Particulate Bone were manufactured from donor (b)(6). A post-processing culture was positive for Micrococcus luteus in one batch manufactured from this donor.\n\nb. During the inspection, the FDA investigator observed processing of HCT\u002FPs, from donor (b)(6) on December 28, 2021, that significantly increased the potential for contamination and did not prevent the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FPs. Specifically, the investigator noted the high velocity return air slots of the (b)(4) Laminar Flow Bench, located along the front edge of the work surface and that provide protection from a “backwash” of dirty air into the work area, were covered with a sterile sheet\u002Fdrape.\n\n2) Failure to validate and approve processes according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests [21 CFR 1271.230(a)]. For example:\n\nYou failed to adequately validate the manufacturing process for the Flexo-Plate, and Flexo-Membrane, and Freeze-Dried Particulate Bone products. Your “Processing of Flexo-plate and Membrane Grafts Process Qualification Summary Report” (dated October 14, 2019) and “Processing of Particulate Tissue Process Qualification Summary Report” (dated October 4, 2019) fail to include in-process microbiological testing to ensure that you are not introducing contamination during processing and that your process removes any contamination present. In addition, the documents noted above do not include any acceptance criteria related to microbiological contamination of HCT\u002FPs or the types of microorganisms typically encountered on such HCT\u002FPs.\n\n3) Failure to monitor environmental conditions where they could reasonably be expected to cause contamination or cross contamination of HCT\u002FPs or equipment, or accidental exposure of HCT\u002FPs to communicable disease agents [21 CFR 1271.195(c)]. For example:\n\nYour January 2020 through November 2021 processing session logs indicate that you conduct environmental monitoring for microorganisms approximately (b)(4). Additionally, you do not perform environmental monitoring during processing. The introduction, transmission, or spread of communicable diseases could reasonably be expected to occur during processing, therefore, you would be expected to perform environmental monitoring for microorganisms during processing.\n\n4) Failure to investigate HCT\u002FP deviations and trends of HCT\u002FP deviations relating to core CGTP requirements. Under the applicable regulation, each investigation must include a review and evaluation of the HCT\u002FP deviation, the efforts made to determine the cause, and the implementation of corrective action(s) to address the HCT\u002FP deviation and prevent recurrence [21 CFR 1271.160(b)(6)]. Specifically:\n\na. After the issuance of an Untitled Letter dated July 22, 2019, you submitted an initial HCT\u002FP deviation report to FDA on September 17, 2019, regarding the distribution of HCT\u002FPs after receipt of positive post-processing cultures. You submitted supplemental information on November 1, 2019, and April 14, 2020. The deviation reports stated you performed an investigation and proposed the reason for the positive post-processing cultures as inadvertent contamination of the sample at the microbiology laboratory when the plastic pouch containing the sample was opened by the testing laboratory that performed the microbiological testing.\n\nAs noted above, you continued to have positive post-processing cultures. You subsequently opened 22 investigations of positive post-processing cultures for bone products processed between April 2020 and December 2021; however, the investigations were closed and once again, you failed to identify corrective actions to address the ongoing deviations and to prevent their recurrence. For example:\n\ni. On May 24, 2021, post-processing cultures for Freeze-Dried Particulate Bone from donor (b)(6) tested positive for Stenotrophomonas maltophilia and Pseudomonas aeruginosa. You opened “HCT\u002FP Deviation #005” after the initiation of the inspection and closed the investigation on December 7, 2021.\n\nii. On May 8, 2020, post-processing cultures for Freeze-Dried Particulate Bone from donor (b)(6) tested positive for Micrococcus luteus. You opened “HCT\u002FP Deviation #001” after the initiation of the inspection and closed the investigation on December 7, 2021.\n\nb. Between January 2020 and November 2021, you performed environmental monitoring prior to cleaning your processing room, which resulted in 10 positive microbiological cultures from the (b)(4), one positive microbiological culture from the (b)(4) used for multiple processing steps to include (b)(4), and one positive microbiological culture from the (b)(4) Laminar Flow Bench. For example:\n\ni. On July 29, 2021, an environmental settling plate (S-072221-09235) from the (b)(4) table tested positive for Fungi, and Bacillus species (not anthracis). You opened “HCT\u002FP Deviation #E002” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\n\nii. On July 12, 2021, an environmental settling plate (S-070421-03649) from the (b)(4) Laminar Flow Bench tested positive for gram-positive cocci and Staphylococcus petrasii. You opened “HCT\u002FP Deviation #E001” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\n\niii. On September 8, 2020, an environmental touch plate (S-090220-08144) from the (b)(4) tested positive for Bacillus species (not anthracis), coagulase-negative Staphylococcus, and Bacillus marisflavi. You opened “HCT\u002FP Deviation #E-006” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\n\nThe deviations identified above are not intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure that your establishment is operating in compliance with all the applicable regulatory requirements. You are responsible for reviewing your firm’s operations as a whole to ensure that you fully comply with the law.\n\nWe acknowledge receipt of your letter dated February 23, 2022, in response to the Form FDA-483, issued to your establishment at the close of the inspection. We have reviewed the corrective actions outlined in the response and we have the following comments:\n\n1. In your response to Observation 1, under paragraph 1(a), your revised SOP 110-006, Release of Processed Tissues states, “... in the event of a positive culture(s) the entire number of batches processed from the same donor during a processing session will be discarded.” Your response does not address your plan for the HCT\u002FPs you have already processed in violation of 21 CFR 1271 that have already been distributed, as well as the HCT\u002FPs that currently remain in storage.\n\n2. In response to Observation 2, under paragraph 2(b) you stated you would, “Revalidate entire process for Processing of Flexo-Plate & Flexo-Membrane Grafts and Particulate Tissue.” We note that under 21 CFR 1271.230(a), process validation must be performed before manufacturing HCT\u002FPs. Your response does not indicate that you will halt processing of Flexo-Plate & Flexo-Membrane Grafts and Particulate Tissue products until your processes have been validated.\n\n3. In response to Observations 4 and 5, you stated that “CAPA#002, Manufacturing monitoring to mitigate contamination” and “CAPA#003, Environmental monitoring” were initiated as corrective actions and that they would be completed by April 2022. Your changes will be reviewed during the next inspection of your establishment to confirm compliance with 21 CFR 1271.\n\n4. In response to Observation 6, you stated that CAPA #001, “Quality Program Continuous Improvement and Enforcement” was initiated that includes drafting a new SOP on how to perform investigations detailing root cause analysis to be completed by April 2022. Your changes will be reviewed during the next inspection of your establishment to confirm compliance with 21 CFR 1271.\n\nYou should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your product is not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame within which the remaining corrections will be completed.\n\nGiven the seriousness of these violations, we also request your attendance at a Regulatory Meeting, within 30 calendar days of receipt of this letter, to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. We will host the meeting virtually on Zoom. This meeting will also allow you to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Colleen Aspinwall, Compliance Officer, at (561) 416-1065, ext. 1105 or by email at Colleen.Aspinwall@fda.hhs.gov for confirmation of the meeting date and time. A call-in phone number for the Zoom meeting will be provided at that time.\n\nYour response should be emailed to Colleen.Aspinwall@fda.hhs.gov. If you should have any questions, please contact Colleen Aspinwall, Compliance Officer, at (561) 416-1065, ext. 1105 or via email.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division I","OsteoLife Biomedical I LLC","osteolife-biomedical-i-llc-626889-03312022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fosteolife-biomedical-i-llc-626889-03312022","2026-10-26T08:09:39.546205+00:00","2022-05-31","626889","Biologics","Theodore I. Malinin, MD","2026-08-20T01:51:41.829+00:00","VIA UPS","2022-03-31",{"id":56,"raw":57,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":19,"fei_number":20,"letter_url":67,"updated_at":68,"action_type":23,"case_status":24,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":20,"issuing_office":61,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":20,"reference_number":20,"action_taken_date":75,"medical_device_id":20,"response_letter_date":20},952,[58,59,60,61,62,13,13,13],"\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-09T04:00:00Z\">04\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025\">Noah Medical Corporation\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FManufacture\u002FPacking\u002FStorage\u002FInstallation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Zhang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Noah Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2075 Zanker Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Jose\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95131\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jianzhang@noahmed.com\"> jianzhang@noahmed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #702414\u003C\u002Fp>\u003Cp>April 09, 2025\u003Cbr>\u003Cbr>Dear Ms. Zhang:\u003C\u002Fp>\u003Cp>During an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\u003C\u002Fp>\u003Cp>a. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\u003C\u002Fp>\u003Cp>b. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\u003C\u002Fp>\u003Cp>a. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\u003C\u002Fp>\u003Cp>i. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\u003C\u002Fp>\u003Cp>ii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\u003C\u002Fp>\u003Cp>iii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\u003C\u002Fp>\u003Cp>b. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\u003C\u002Fp>\u003Cp>c. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\u003C\u002Fp>\u003Cp>i. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\u003C\u002Fp>\u003Cp>ii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\u003C\u002Fp>\u003Cp>Specifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\u003C\u002Fp>\u003Cp>a. Your firm failed to adequately conduct design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> biopsy tools, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and used the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration of the bronchoscope instead of \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\u003C\u002Fp>\u003Cp>b. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\u003C\u002Fp>\u003Cp>i. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\u003C\u002Fp>\u003Cp>ii. Protocol #TP-008, Revision E, describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\u003C\u002Fp>\u003Cp>iii. Protocol #TP-099, Revision B, relating to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> configurations)” and Summary Report #TR-378, Revision A.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\u003C\u002Fp>\u003Cp>a. NCR 0367 (Dated 04\u002F11\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak test due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the working channels (part \u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, your firm did not conduct investigation to identify the root cause(s) of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>b. NCR 0605 (Dated 09\u002F20\u002F2024) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the other \u003Cstrong>(b)(4)\u003C\u002Fstrong> failures were due to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>c. NCR 0071 (Dated 07\u002F27\u002F2023) involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\u003C\u002Fp>\u003Cp>Specifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516 (part number \u003Cstrong>(b)(4)\u003C\u002Fstrong>), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the \u003Cstrong>(b)(4)\u003C\u002Fstrong> upon the “Galaxy, Cart, \u003Cstrong>(b)(4)\u003C\u002Fstrong>” CRB-1516.\u003C\u002Fp>\u003Cp>We reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\u003C\u002Fp>\u003Cp>Your firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>Your firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>Cc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Zhang\n\nRecipient Title\n\nChief Executive Officer\n\nNoah Medical Corporation\n\n2075 Zanker Road\n\nSan Jose, CA 95131\n\nUnited States\n\njianzhang@noahmed.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #702414\nApril 09, 2025\n\nDear Ms. Zhang:\nDuring an inspection of your firm located at 2075 Zanker Road, San Jose, CA 95131 on October 28, 2024, through November 26, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bronchoscopes and accessories (branded as the Galaxy System). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Richard W. Reeves, Vice President Quality Assurance and Regulatory Affairs, dated December 18, 2024, and January 21, 2025, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm1. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your firm failed to adequately establish your “Corrective and Preventive Action (CAPA)” procedure (SOP-019 Rev. B, Effective Date: 10\u002F30\u002F2024), as your firm did not adequately conduct and document CAPA investigations. For example, according to your procedure, a Corrective Action\u002FPreventive Action (CAPA) process shall be established to ensure “investigations are conducted to a degree sufficient to determine the root cause.” However, 2 out of 17 CAPA records selected for review by our investigators did not identify the root causes and necessary corrective and preventive actions as required by your CAPA procedure. The following describes the two CAPA records:\na. CAPA 24-007 dated 9\u002F11\u002F2024: Your firm failed to conduct adequate investigations as required by your CAPA procedure. For example, your firm failed to explore sufficiently to determine the root cause for “biopsy tools couldn’t pass through bronchoscope’s working channels.” You did not investigate, sufficiently to determine the root cause, the lot-to-lot variation of the distal end measurements of the working channels and how it may impact your root cause analysis.\nb. CAPA 23-005 dated 4\u002F14\u002F2023: This CAPA record reported two scope pouches leaking due to the (b)(4) poking holes in the pouches during shelf-life\u002Fpackaging transportation study Protocol “Design Verification Protocol for Bronchoscope Packaging,” (DOC: TP-099 Rev. B), and test report #WP-12154A. During execution of the (b)(4) aging testing of the sterile bronchoscope, a test failure was noted during a gross leak testing of the scope pouches. Your firm did not evaluate how many scope pouches were leaking to identify other potential causes of the failed leak test, such as quality issues with your suppliers. Subsequently, your scope pouches failed leak test during a (b)(4) aging study (test report number #WP-16128A), but your firm did not document the cause of the leak nor reference this failed leak test in CAPA 23-005.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-028. You indicate that your firm made immediate corrections to CAPA 24-007; plans to contract with a third-party to retrospectively review all open and closed CAPAs, including the CAPAs cited during the last inspection; revised the CAPA process; and completed relevant training on the revised CAPA procedure including revised work instructions. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA 24-028 record.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, your complaint procedure, “Complaint Management,” (SOP-025, Rev. G, Effective Date: 10\u002F28\u002F2024) has not been adequately established as your firm did not adequately conduct and\u002For document complaint investigations. For example,\na. Your procedure indicates complaint investigations are conducted to “determine the cause of any product defects and\u002For malfunctions, whether product met specifications, or whether product specifications were met, but were inadequate.” Your firm did not follow your procedure as exemplified below:\ni. Complaint #00003531 described a failure to acquire live video feed upon attaching the scope to the instrument driving mechanism (IDM). Your firm did not adequately investigate the cause(s) of camera image loss.\nii. Complaint #00002229 involved a user experiencing scope buckling errors due to severe kink in the distal area and the user had to replace with another scope. However, your firm did not investigate cause(s) for the kinks.\niii. Complaint #00003614 described a patient experiencing excessive bleeding during Galaxy-assisted procedure. Complaint record states “scope buckling malfunction was observed.” However, your firm did not identify cause(s) for scope buckling.\nb. Your procedure states complaint “investigation examples may include, but is not limited to … batch record review to determine if there were nonconformances, material used, or process steps that could have contributed to the complaint.” For complaint #00003610 involving a patient who had pneumothorax while undergoing a Galaxy-assisted biopsy procedure for a 14mm lesion in the left upper lobe, the patient got a chest tube insert and was admitted to the hospital for 3 days. Your firm did not review batch records and other quality data sources for the bronchoscope used in this procedure to investigate and determine whether your device could have contributed to the patient’s injury.\nc. Your procedure states that “additional information from the complainant may be required to process a complaint” and that “various methods of communication … should be attempted in order to make a good faith effort to contact the complainant.” However, your firm failed to conduct and\u002For document a good faith effort to obtain additional information to support the complaint investigations. For example:\ni. Complaint #00003544 has a death reported due to excess bleeding when a patient was undergoing a Galaxy-assisted bronchoscopy procedure. According to your firm’s representative and associated complaint record, the physician stated that “the patient had possibly forgotten to stop taking blood thinners” and patient possibly was “puncture[d] by biopsy forceps.” Your firm’s Clinical Engineer reviewed the video of the procedure and said she could not see the forceps puncturing the blood vessel because there was too much blood blocking the camera view. Your firm did not make any attempt(s) to verify the causes further.\nii. Complaint #00003337 involves a procedure that was aborted due to broken joysticks on two different controllers resulting in the scope drifting significantly into the patient’s right upper lobe of the lung. There was no documented information on when the patient was rescheduled for another procedure nor if the patient experienced any adverse event(s) after aborted procedures.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-025, CAPA 24-026, and CAPA 24-015. Your responses indicate that your firm has made some progress including completion of the root cause investigation for CAPA 24-015. However, the CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n3. Failure to establish and maintain procedures for design control, as required by 21 CFR 820.30.\nSpecifically, your design control procedure, “Design Controls” (SOP-002, Rev. G, Effective Date: 10\u002F21\u002F2024), has not been adequately established.2 For example, your design control procedure states that “Design verification and validation shall be conducted in accordance with SOP-033…to ensure design outputs meet the design input requirements and the product meets its intended use.” However, your firm failed to establish the procedure as follows:\na. Your firm failed to adequately conduct design validation for the (b)(4) biopsy tools, such as (b)(4), listed on page 23 of IFU Rev J, Effective Date: 09\u002F25\u002F2024. During design validation, your firm only performed design validation for the (b)(4) and used the (b)(4) as the worst-case tool for biopsy tool passage. Furthermore, your firm only tested biopsy tool passage in a (b)(4) configuration of the bronchoscope instead of (b)(4) configuration to account for bending of the bronchoscope. Your firm initiated CAPA 24-007 after the complaint trend associated with biopsy tools not passing through working channel “exceeded the required action threshold.”\nb. Your procedure failed to define the requirements to test sterility as part of the shelf-life validations. Your bronchoscopes are sold as sterile with an expiration date of two years, but your firm did not test product sterility as part of the shelf-life validations in the following protocols:\ni. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan” and Summary Report #TR-087, Revision C.\nii. Protocol #TP-008, Revision E, describing the (b)(4) aging study, titled: “Galaxy Bronchoscope Verification Test Plan,” and Summary Report WP-16128A, Date Reviewed 05\u002F08\u002F2024.\niii. Protocol #TP-099, Revision B, relating to the (b)(4) aging study, titled: “Design Verification Protocol for Bronchoscope Packaging (includes (b)(4) and (b)(4) configurations)” and Summary Report #TR-378, Revision A.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-016 and CAPA 24-018. You indicate “as part of the Corrective Action, all instances of Design Verification and Validation of Requirements are being reviewed and where assumptions were made, these are being tested against documented evidence” (your firm’s response dated January 21, 2025). The CAPA activities are still ongoing for all three CAPA records, and your responses do not clearly specify the target completion dates for each overall CAPA record.\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nSpecifically, your procedure, “Nonconforming Material,” (SOP-018 Rev. G, Effective Date: 09\u002F24\u002F2024,), has not been adequately implemented. Your firm failed to conduct investigations to identify the root cause(s) as required by your nonconforming material procedure. For example:\na. NCR 0367 (Dated 04\u002F11\u002F2024) involves (b)(4) bronchoscopes failing leak test due to (b)(4) in the working channels (part (b)(4)). However, your firm did not conduct investigation to identify the root cause(s) of the (b)(4) nor implement a SCAR with your supplier.\nb. NCR 0605 (Dated 09\u002F20\u002F2024) involves (b)(4) bronchoscopes failing leak tests. One failure was due to the working channel not adequately bonded to the (b)(4), and the other (b)(4) failures were due to (b)(4). However, your firm did not conduct investigation to identify the root cause(s) for the inadequate bonding nor the exposed (b)(4).\nc. NCR 0071 (Dated 07\u002F27\u002F2023) involves (b)(4) working channels found to have kinks. However, your firm failed to investigate to identify the root cause(s) for the kinks nor implement a SCAR with your supplier.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-021. Your responses indicate that your firm plans to update your procedures, conduct training once the revised procedures are complete, and address immediate issues including review of all NCRs to date (starting from May 2023, approximately (b)(4) NCRs) and identify those which require investigation or revisions. Also, you indicate that there was immediate containment for the NCRs cited during the recent inspection and your firm issued SCAR number 24-010 to your supplier to determine the root cause of working channel defects. However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\n5. Failure to establish and maintain procedures for rework, to include retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications, as required by 21 CFR 820.90(b)(2). Rework and reevaluation activities, including a determination of any adverse effect from the rework upon the product, shall be documented in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\nSpecifically, your procedure, “Rework and Deviation,” (SOP-020 Rev. B, Effective Date: 11\u002F28\u002F2022), has not been adequately established. For example, your Rework and Deviation procedure failed to include the requirement for determining whether there has been any adverse effect from rework upon the product when documenting rework and reevaluation activities. For example, the DHR for “Galaxy, Cart, (b)(4)” CRB-1516 (part number (b)(4)), relates to nonconformance #108, which described a nonconformance with an instrument driving mechanism ((b)(4)) on the Galaxy System robot. This nonconformance resulted in frozen bronchoscope camera images. The (b)(4) were replaced. However, your firm did not document a determination of whether there has been any adverse effect from reworking the (b)(4) upon the “Galaxy, Cart, (b)(4)” CRB-1516.\nWe reviewed your responses, and their adequacy cannot be determined at this time. Your responses indicate that your firm initiated CAPA 24-022. Your responses indicate that you have revised your Rework and Deviation procedure and plan to conduct “a retrospective review of NCRs, rework, complaints and field repairs for all shipped systems to date as well as those in inventory to determine if any adverse effects are evident, and plan to implement corrections” (your response dated January 21, 2025). However, the CAPA activities are still ongoing, and your responses do not clearly specify the target completion date for the overall CAPA record.\nOur inspection also revealed that your firm’s Galaxy Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the devices that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint #00003935 and #00003614 reasonably suggests that during a procedure where your firm’s Galaxy System was used, the patients sustained injuries resulting in bleeding that were treated with irrigation and suction (Complaint #00003935) and Levophed administration (Complaint #00003614). We determined that these interventions were necessitated to prevent permanent impairment of a body function or permanent damage to a body structure (21 CFR 803.3(w)(3)). Your firm became aware of Complaint #00003935 on August 21, 2024, and FDA has not yet received an MDR for the corresponding MDR reportable event.\nYour firm became aware of Complaint #00003614 on July 24, 2024. Although the corresponding MDR #3021325287-2024-00024 was received by FDA on January 13, 2025, it was received beyond the 30-calendar-day timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. The responses indicate that your firm initiated a root cause investigation, plans to streamline its MDR reporting process, and is conducting a retrospective review of complaints for reportability. However, in the responses, your firm did not include documentation or evidence to demonstrate that the systemic corrective actions have been fully implemented, as these efforts are still ongoing.\nOur inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, the document titled “Medical Device Reporting,” Doc# SOP-026, Rev. C, dated 10\u002F28\u002F2024, was presented as your firm’s written MDR procedure. After reviewing the MDR procedure, the following deficiencies were noted:\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definitions of the terms “caused or contributed” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nYour firm’s responses did not address the noted procedural deficiencies, as these were not included in the FDA Form 483.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: cdrhenforcement@fda.hhs.gov. Please include in the subject line, CMS case #702414 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh Adams, Compliance Officer, at lindalinh.adams@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCc: Sam Mostafavi, Regulatory Advisor\u002F Management Representative, at sammostafavi@noahmed.com\n_______________________\n1 FDA also received a response dated February 18, 2025. This letter does not address that response given timing considerations. That response will be considered along with any response to this letter.\n2 Under 21 CFR 820.3(k), “establish” means define, document (in writing or electronically), and implement.","Noah Medical Corporation","noah-medical-corporation-702414-04092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoah-medical-corporation-702414-04092025","2026-10-26T08:09:34.20429+00:00","2025-04-22","702414","Medical Devices","Jian Zhang","2026-08-19T16:52:23.305+00:00","VIA Electronic Mail","2025-04-09",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":20,"letter_url":89,"updated_at":90,"action_type":23,"case_status":24,"posted_date":91,"marcs_cms_no":92,"product_type":71,"closeout_date":20,"issuing_office":61,"recipient_name":93,"body_fetched_at":94,"delivery_method":74,"recipient_title":20,"reference_number":20,"action_taken_date":95,"medical_device_id":20,"response_letter_date":20},63,[79,80,81,61,82,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026\">BMC Medical Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BMC Medical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 16 Lize Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room 10, 17F Building 4, Huiya Plaza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fengtai Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>, \u003Cspan>100073\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 725759\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Xu:\u003C\u002Fp>\u003Cp>During an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Your firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\u003C\u002Fp>\u003Cp>Furthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ or ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ and a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong>, these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\u003C\u002Fp>\u003Cp>FDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\u003C\u002Fp>\u003Cp>For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Correction and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Xu\n\nRecipient Title\n\nPresident\n\nBMC Medical Co., Ltd.\n\nNo. 16 Lize Road\n\nRoom 10, 17F Building 4, Huiya Plaza\n\nFengtai Qu\n\nBeijing Shi, 100073\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 725759\nMay 20, 2026\nDear Mr. Xu:\nDuring an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nUnapproved Device Violations\nOur inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYour firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\nFurthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘(b)(4)’ or ‘(b)(4)’ and a new (b)(4) was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new (b)(4) chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of (b)(4) represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new (b)(4), these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new (b)(4) PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\nFDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\nFor further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\nCorrection and Removals Violations\nOur inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\n1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in (b)(4) to (b)(4). The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\nYour firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\n(b)(4), (b)(6)","BMC Medical Co., Ltd.","bmc-medical-co-ltd-725759-05202026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026","2026-10-26T08:08:06.951272+00:00","2026-06-30","725759","Jian Xu","2026-08-19T04:32:13.877+00:00","2026-05-20",{"id":97,"raw":98,"subject":102,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":107,"fei_number":20,"letter_url":108,"updated_at":109,"action_type":23,"case_status":24,"posted_date":110,"marcs_cms_no":111,"product_type":71,"closeout_date":20,"issuing_office":61,"recipient_name":112,"body_fetched_at":113,"delivery_method":74,"recipient_title":20,"reference_number":20,"action_taken_date":110,"medical_device_id":20,"response_letter_date":20},3309,[99,100,101,61,102,13,13,13],"\u003Ctime datetime=\"2021-06-10T16:00:00Z\">06\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-10T04:00:00Z\">06\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnova-medical-group-inc-614819-06102021\">Innova Medical Group, Inc.\u003C\u002Fa>","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Daniel J. Elliot\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Innova Medical Group, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>800 E. Colorado Blvd., Suite 288\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pasadena\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Daniel.elliott@innovamedgroup.com\"> Daniel.elliott@innovamedgroup.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS # 614819\u003C\u002Fp>\n\n\u003Cp>June 10, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Elliot:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Innova Medical Group, Inc., located at 800 E. Colorado Blvd., Suite 288, Pasadena, CA from March 15 through April 9, 2021. In addition, your other manufacturing facilities at 495 N. Berry Street, Brea, CA, and MPS Medical, Inc. at 785 Challenger Street, Brea, CA, were also inspected from March 15 through April 8, 2021. During these inspections, the FDA investigators determined that your firm is a medical device manufacturer and initial distributor\u002Fimporter of the SARS-CoV-2 Antigen Rapid Qualitative Test (also distributed under the names INNOVA COVID-19 Self-Test Kit (3T Configuration), INNOVA SARS-CoV-2-Antigen Rapid Qualitative Test (7T Configuration), and INNOVA SARS-CoV-2-Antigen Rapid Qualitative Test (25T Configuration)). Based on our review, your SARS-CoV-2 Antigen Rapid Qualitative Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the SARS-CoV-2 Antigen Rapid Qualitative Test has been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, the product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to cease the sale and distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspections also revealed that the 25T Configuration and 7T Configuration of the SARS-CoV-2 Antigen Rapid Qualitative Test are misbranded within the meaning of section 502(a) of the Act, 21 U.S.C. § 352(a), in that the devices’ respective labeling was false or misleading. More specifically, the labeling distributed for your 25T Configuration devices included a “Clinical Performance” section, which claimed a Relative Sensitivity of 96% (88.75-99.17% CI); a Relative Specificity of 100% (98.34-100% CI); and an Accuracy of 98.98% (97.06-99.79% CI). This level of clinical performance for the 25T Configuration devices appears unsupported by any clinical data including both clinical performance data submitted to FDA in your Emergency Use Authorization (EUA) request for the SARS-CoV-2 Antigen Rapid Qualitative Test and in published reports of clinical studies of the SARS-CoV-2 Antigen Rapid Qualitative Test.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Similarly, the labeling distributed for your 7T Configuration devices included a “Performance of Prospective Clinical Study” section based on a prospective clinical study conducted by “third-party investigators in UK in September and October 2020” which claimed a Positive Percent Agreement of 81.4% (74.3-88.4% CI). This PPA for the 7T Configuration devices does not appear to align with the PPA observed in the phase 3b prospective clinical study conducted in the United Kingdom.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, the clinical performance estimates reported in the labeling of the 25T Configuration and 7T Configurations devices are false or misleading as they do not accurately reflect the performance estimates observed during the clinical studies of your devices.\u003C\u002Fp>\n\n\u003Cp>Separate and apart from the foregoing issues, FDA further notes that the clinical study data you submitted in your EUA request for the SARS-CoV-2 Antigen Rapid Qualitative Test was identical to data previously provided by other manufacturers in their separate EUA requests. The data reliability and accuracy issues noted herein raise significant concerns that the performance of the SARS-CoV-2 Antigen Rapid Qualitative Test has not been adequately established, and that the products distributed by Innova without FDA approval, clearance, or authorization could present a serious risk to the public health.\u003C\u002Fp>\n\n\u003Cp>The inspections also revealed that the SARS-CoV-2 Antigen Rapid Qualitative Test is adulterated with the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, is manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated April 30, 2021, from Eric Grubel, Chief Operating Officer, and the following update dated May 28, 2021, from Janet L. Michener Whipple, Interim Vice President of Quality, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on April 9, 2021. We address your responses below. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. For example:\u003C\u002Fp>\n\n\u003Cp>Our investigators observed your firm has executed contractual agreements with at least \u003Cstrong>(b)(4) \u003C\u002Fstrong>distributors for the commercial promotion and sale of the SARS-CoV-2 Antigen Rapid Qualitative Tests in the United States and has distributed more than \u003Cstrong>(b)(4) \u003C\u002Fstrong>test kits to US customers. According to your firm, these Tests have been shipped to several customers to Indiana, New York, Vermont, and Oregon during January and February of 2021. No records were maintained to demonstrate that these devices were approved for release.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge you have opened CAPA #2021-002 and created new standard operating procedures to address Purchase Management and Control and Distribution of your products, in addition to completing personnel training on the new procedures and processes. You did not provide evidence of implementation of your new SOPs, or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for incoming product and finished device acceptance activities. There are no acceptance records of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure that specified requirements for your devices are met and meets the acceptance criteria. For example,\u003C\u002Fp>\n\n\u003Cp>Your firm distributed SARS-CoV-2 Antigen Rapid Qualitative Tests. These test kits were not inspected, tested, or otherwise verified after receiving it from your contract manufacturer in China or prior to shipment to the end users. Consequently, the 7T and 3T boxes were shipped to customers with the incorrect Instructions for Use (IFU).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge you opened CAPA #2021-003 and created a new acceptance activity work instruction for incoming and finished devices, and completed personnel training on the new procedures and work instructions. You did not provide evidence of implementation of your new work instruction and evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. We also acknowledge that your firm initiated a voluntary recall of certain lots of 3T and 7T test kits distributed for non-investigational use only. It is unclear how you plan to address incorrectly labeled products distributed for investigational use. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. During the inspection, the investigators observed 13 cartons of SARS-CoV-2 Antigen Rapid Qualitative Tests co-mingled in a storage room with multiple cartons of returned nonconforming test kits, samples used for product evaluation, and damaged controls, all of which was slated for destruction. The 13 cartons of test kits were not identified as nonconforming and no records were maintained to demonstrate if an investigation was needed or the disposition of nonconforming products.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge that you opened CAPA #2021-004, and created an SOP 9.0, Control of Nonconformances, and completed personnel training on the new procedures. You did not provide adequate evidence of implementation of your new procedure or evidence demonstrating the CAPA is effective in preventing the noted violations from recurring. For example, in your May 28 response you provided the Nonconforming Incident Report, NCR #2021-002, for \u003Cstrong>(b)(4) \u003C\u002Fstrong>tests that were destroyed during the inspection. According to your incident report, an investigation to determine the root cause of the nonconforming product was not required because the “root cause is known as identified during FDA inspection” while your SOP 9.0 requires all product nonconformances to be investigated unless otherwise justified and documented. It is not clear how an FDA inspection justifies not investigating the root cause of the \u003Cstrong>(b)(4) \u003C\u002Fstrong>nonconforming tests. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, Your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: analyzing quality data sources; investigating the cause of nonconformities; identifying the action(s) needed to correct and prevent occurrence or recurrence of nonconformities; verifying or validating the CAPA to ensure the actions implemented are effective; documenting the changes in methods and procedures; disseminating information related to quality problems to appropriate individuals; and submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude the adequacy cannot be determined at this time. We acknowledge your firm has created SOP 10.0, Corrective and Preventive Action, and opened CAPA #2021-001 in accordance with your new procedure, and completed training personnel on the new procedures. However, you did not provide evidence of the effectiveness of your new CAPA procedure as the corrective actions remain in progress, and therefore we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling to ensure that complaints are processed in a uniform and timely manner, oral complaints are documented upon receipt, and complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude the adequacy cannot be determined at this time. We acknowledge that you opened CAPA #2021-006 and created SOP 14.0, Complaint Handling and Failure Investigation, and completed personnel training on the new procedures. However, your response does not indicate whether your firm will conduct a retrospective review of any complaints your firm previously received. While your response states your firm “has not received any complaints regarding its SARVS-CoV-2 Antigen Rapid Qualitative Test”, our investigators noted your storage room was holding damaged product returned from your customers, which appears to fall under section 5.6 of your new complaint procedure. You did not provide evidence of implementation of your new procedure or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for the evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. You did not evaluate your only contract manufacturer of the SARS-CoV-2 Antigen Rapid Qualitative Test system based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge your firm opened CAPA #2021-005 and created new standard operating procedures for purchase management and supplier controls, and completed personnel training on the new procedures. You did not provide evidence of the implementation of your new SOPs, or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your SARS-CoV-2 Antigen Rapid Qualitative Test is misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation include, but is not limited to:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that your firm’s response dated April 30, 2021 is not adequate. In the response, your firm noted that it developed a written MDR procedure, scheduled staff training and planned to assess the effectiveness of corrective actions by July 1. Your response included a copy of your firm’s MDR procedure titled “Medical Device Reporting (MDR and eMDR)”, Document Number: 7.0, Revision 1.0, Effective Date: 4\u002F29\u002F2021. After reviewing your firm’s MDR procedure, we noted that the procedure does not reference a process for identifying and evaluating events involving similar devices to those marketed in the United States (U.S.) as potentially reportable to FDA. Specifically, the procedure notes under the Scope section that it “applies to devices marketed in the United States”. If an event involves a similar device to one legally marketed in the U.S., it may be reportable under the MDR regulation. By not considering events involving similar legally marketed devices, potentially reportable MDRs may not be identified and evaluated for MDR decision making and submission to FDA as required by 21 CFR 803.50 and 21 CFR 803.53.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm did not provide documentation or evidence of implementation of a systematic corrective action to include a retrospective review of its adverse events in accordance with its MDR procedure.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address the violations cited in this letter. Also, federal agencies may be advised of the issuance of Warning Letters about devices and may take your compliance with Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address the violations relating to your firm’s sale or distribution of the SARS-CoV-2 Antigen Rapid Qualitative Test. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted Quality Systems and MDR reporting violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case #614819.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officers, Charles J. Chacko at 214-253-4939, or via email at charles.chacko@fda.hhs.gov or Jamie M. Bumpas at 214-253-5336, or via email at Jamie.bumpas@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&amp;C Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc:\u003C\u002Fp>\n\n\u003Cp>Mr. Eric E. Grubel, COO\u003Cbr>\n800 E. Colorado Blvd., Suite 288\u003Cbr>\nPasadena, CA 91101\u003Cbr>\nEric.grubel@innovamedgroup.com\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See “Preliminary report from the Joint PHE Porton Down &amp; University of Oxford SARS-CoV-2 test development and validation cell: Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass community testing:” published November 8, 2020 available at https:\u002F\u002Fwww.ox.ac.uk\u002Fsites\u002Ffiles\u002Foxford\u002Fmedia_wysiwyg\u002FUK%20evaluation_PHE%20Porton%20Down%20%20University%20of%20Oxford_final.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Id.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDaniel J. Elliot\n\nRecipient Title\n\nChief Executive Officer\n\nInnova Medical Group, Inc.\n\n800 E. Colorado Blvd., Suite 288\n\nPasadena, CA 91101\n\nUnited States\n\nDaniel.elliott@innovamedgroup.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 614819\n\nJune 10, 2021\n\nDear Mr. Elliot:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, Innova Medical Group, Inc., located at 800 E. Colorado Blvd., Suite 288, Pasadena, CA from March 15 through April 9, 2021. In addition, your other manufacturing facilities at 495 N. Berry Street, Brea, CA, and MPS Medical, Inc. at 785 Challenger Street, Brea, CA, were also inspected from March 15 through April 8, 2021. During these inspections, the FDA investigators determined that your firm is a medical device manufacturer and initial distributor\u002Fimporter of the SARS-CoV-2 Antigen Rapid Qualitative Test (also distributed under the names INNOVA COVID-19 Self-Test Kit (3T Configuration), INNOVA SARS-CoV-2-Antigen Rapid Qualitative Test (7T Configuration), and INNOVA SARS-CoV-2-Antigen Rapid Qualitative Test (25T Configuration)). Based on our review, your SARS-CoV-2 Antigen Rapid Qualitative Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the SARS-CoV-2 Antigen Rapid Qualitative Test has been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, the product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to cease the sale and distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”4 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspections also revealed that the 25T Configuration and 7T Configuration of the SARS-CoV-2 Antigen Rapid Qualitative Test are misbranded within the meaning of section 502(a) of the Act, 21 U.S.C. § 352(a), in that the devices’ respective labeling was false or misleading. More specifically, the labeling distributed for your 25T Configuration devices included a “Clinical Performance” section, which claimed a Relative Sensitivity of 96% (88.75-99.17% CI); a Relative Specificity of 100% (98.34-100% CI); and an Accuracy of 98.98% (97.06-99.79% CI). This level of clinical performance for the 25T Configuration devices appears unsupported by any clinical data including both clinical performance data submitted to FDA in your Emergency Use Authorization (EUA) request for the SARS-CoV-2 Antigen Rapid Qualitative Test and in published reports of clinical studies of the SARS-CoV-2 Antigen Rapid Qualitative Test.5 Similarly, the labeling distributed for your 7T Configuration devices included a “Performance of Prospective Clinical Study” section based on a prospective clinical study conducted by “third-party investigators in UK in September and October 2020” which claimed a Positive Percent Agreement of 81.4% (74.3-88.4% CI). This PPA for the 7T Configuration devices does not appear to align with the PPA observed in the phase 3b prospective clinical study conducted in the United Kingdom.6 Accordingly, the clinical performance estimates reported in the labeling of the 25T Configuration and 7T Configurations devices are false or misleading as they do not accurately reflect the performance estimates observed during the clinical studies of your devices.\n\nSeparate and apart from the foregoing issues, FDA further notes that the clinical study data you submitted in your EUA request for the SARS-CoV-2 Antigen Rapid Qualitative Test was identical to data previously provided by other manufacturers in their separate EUA requests. The data reliability and accuracy issues noted herein raise significant concerns that the performance of the SARS-CoV-2 Antigen Rapid Qualitative Test has not been adequately established, and that the products distributed by Innova without FDA approval, clearance, or authorization could present a serious risk to the public health.\n\nThe inspections also revealed that the SARS-CoV-2 Antigen Rapid Qualitative Test is adulterated with the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, is manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated April 30, 2021, from Eric Grubel, Chief Operating Officer, and the following update dated May 28, 2021, from Janet L. Michener Whipple, Interim Vice President of Quality, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on April 9, 2021. We address your responses below. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. For example:\n\nOur investigators observed your firm has executed contractual agreements with at least (b)(4) distributors for the commercial promotion and sale of the SARS-CoV-2 Antigen Rapid Qualitative Tests in the United States and has distributed more than (b)(4) test kits to US customers. According to your firm, these Tests have been shipped to several customers to Indiana, New York, Vermont, and Oregon during January and February of 2021. No records were maintained to demonstrate that these devices were approved for release.\n\nWe reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge you have opened CAPA #2021-002 and created new standard operating procedures to address Purchase Management and Control and Distribution of your products, in addition to completing personnel training on the new procedures and processes. You did not provide evidence of implementation of your new SOPs, or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\n2. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm has not established procedures for incoming product and finished device acceptance activities. There are no acceptance records of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure that specified requirements for your devices are met and meets the acceptance criteria. For example,\n\nYour firm distributed SARS-CoV-2 Antigen Rapid Qualitative Tests. These test kits were not inspected, tested, or otherwise verified after receiving it from your contract manufacturer in China or prior to shipment to the end users. Consequently, the 7T and 3T boxes were shipped to customers with the incorrect Instructions for Use (IFU).\n\nWe reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge you opened CAPA #2021-003 and created a new acceptance activity work instruction for incoming and finished devices, and completed personnel training on the new procedures and work instructions. You did not provide evidence of implementation of your new work instruction and evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. We also acknowledge that your firm initiated a voluntary recall of certain lots of 3T and 7T test kits distributed for non-investigational use only. It is unclear how you plan to address incorrectly labeled products distributed for investigational use. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\n3. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established and maintained procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. During the inspection, the investigators observed 13 cartons of SARS-CoV-2 Antigen Rapid Qualitative Tests co-mingled in a storage room with multiple cartons of returned nonconforming test kits, samples used for product evaluation, and damaged controls, all of which was slated for destruction. The 13 cartons of test kits were not identified as nonconforming and no records were maintained to demonstrate if an investigation was needed or the disposition of nonconforming products.\n\nWe reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge that you opened CAPA #2021-004, and created an SOP 9.0, Control of Nonconformances, and completed personnel training on the new procedures. You did not provide adequate evidence of implementation of your new procedure or evidence demonstrating the CAPA is effective in preventing the noted violations from recurring. For example, in your May 28 response you provided the Nonconforming Incident Report, NCR #2021-002, for (b)(4) tests that were destroyed during the inspection. According to your incident report, an investigation to determine the root cause of the nonconforming product was not required because the “root cause is known as identified during FDA inspection” while your SOP 9.0 requires all product nonconformances to be investigated unless otherwise justified and documented. It is not clear how an FDA inspection justifies not investigating the root cause of the (b)(4) nonconforming tests. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\n4. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, Your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: analyzing quality data sources; investigating the cause of nonconformities; identifying the action(s) needed to correct and prevent occurrence or recurrence of nonconformities; verifying or validating the CAPA to ensure the actions implemented are effective; documenting the changes in methods and procedures; disseminating information related to quality problems to appropriate individuals; and submitting relevant information on quality problems for management review.\n\nWe reviewed your firm’s response and conclude the adequacy cannot be determined at this time. We acknowledge your firm has created SOP 10.0, Corrective and Preventive Action, and opened CAPA #2021-001 in accordance with your new procedure, and completed training personnel on the new procedures. However, you did not provide evidence of the effectiveness of your new CAPA procedure as the corrective actions remain in progress, and therefore we are unable to fully assess the adequacy of your response.\n\n5. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling to ensure that complaints are processed in a uniform and timely manner, oral complaints are documented upon receipt, and complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\nWe reviewed your firm’s response and conclude the adequacy cannot be determined at this time. We acknowledge that you opened CAPA #2021-006 and created SOP 14.0, Complaint Handling and Failure Investigation, and completed personnel training on the new procedures. However, your response does not indicate whether your firm will conduct a retrospective review of any complaints your firm previously received. While your response states your firm “has not received any complaints regarding its SARVS-CoV-2 Antigen Rapid Qualitative Test”, our investigators noted your storage room was holding damaged product returned from your customers, which appears to fall under section 5.6 of your new complaint procedure. You did not provide evidence of implementation of your new procedure or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\n6. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for the evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. You did not evaluate your only contract manufacturer of the SARS-CoV-2 Antigen Rapid Qualitative Test system based on their ability to meet specified requirements, including quality requirements.\n\nWe reviewed your firm’s response and conclude that the adequacy cannot be determined at this time. We acknowledge your firm opened CAPA #2021-005 and created new standard operating procedures for purchase management and supplier controls, and completed personnel training on the new procedures. You did not provide evidence of the implementation of your new SOPs, or evidence demonstrating that your CAPA is effective in preventing noted violations from recurring. As your corrective actions remain in progress, we are unable to fully assess the adequacy of your response.\n\nOur inspection also revealed that your SARS-CoV-2 Antigen Rapid Qualitative Test is misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation include, but is not limited to:\n\n7. Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nWe reviewed your firm’s response and conclude that your firm’s response dated April 30, 2021 is not adequate. In the response, your firm noted that it developed a written MDR procedure, scheduled staff training and planned to assess the effectiveness of corrective actions by July 1. Your response included a copy of your firm’s MDR procedure titled “Medical Device Reporting (MDR and eMDR)”, Document Number: 7.0, Revision 1.0, Effective Date: 4\u002F29\u002F2021. After reviewing your firm’s MDR procedure, we noted that the procedure does not reference a process for identifying and evaluating events involving similar devices to those marketed in the United States (U.S.) as potentially reportable to FDA. Specifically, the procedure notes under the Scope section that it “applies to devices marketed in the United States”. If an event involves a similar device to one legally marketed in the U.S., it may be reportable under the MDR regulation. By not considering events involving similar legally marketed devices, potentially reportable MDRs may not be identified and evaluated for MDR decision making and submission to FDA as required by 21 CFR 803.50 and 21 CFR 803.53.\n\nAdditionally, your firm did not provide documentation or evidence of implementation of a systematic corrective action to include a retrospective review of its adverse events in accordance with its MDR procedure.\n\nYour firm should take prompt action to address the violations cited in this letter. Also, federal agencies may be advised of the issuance of Warning Letters about devices and may take your compliance with Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address the violations relating to your firm’s sale or distribution of the SARS-CoV-2 Antigen Rapid Qualitative Test. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted Quality Systems and MDR reporting violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case #614819.\n\nIf you have questions about the contents of this letter, please contact Compliance Officers, Charles J. Chacko at 214-253-4939, or via email at charles.chacko@fda.hhs.gov or Jamie M. Bumpas at 214-253-5336, or via email at Jamie.bumpas@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&C Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nCc:\n\nMr. Eric E. Grubel, COO\n\n800 E. Colorado Blvd., Suite 288\n\nPasadena, CA 91101\n\nEric.grubel@innovamedgroup.com\n\n__________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.\n\n5 See “Preliminary report from the Joint PHE Porton Down & University of Oxford SARS-CoV-2 test development and validation cell: Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass community testing:” published November 8, 2020 available at https:\u002F\u002Fwww.ox.ac.uk\u002Fsites\u002Ffiles\u002Foxford\u002Fmedia_wysiwyg\u002FUK%20evaluation_PHE%20Porton%20Down%20%20University%20of%20Oxford_final.pdf.\n\n6 Id.","Innova Medical Group, Inc.","innova-medical-group-inc-614819-06102021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnova-medical-group-inc-614819-06102021","2026-10-26T08:08:59.098007+00:00","2021-06-10","614819","Daniel J. Elliot","2026-08-20T03:04:36.988+00:00",{"id":115,"raw":116,"subject":121,"body_html":122,"body_text":123,"firm_name":124,"letter_id":125,"created_at":107,"fei_number":20,"letter_url":126,"updated_at":127,"action_type":23,"case_status":24,"posted_date":128,"marcs_cms_no":129,"product_type":130,"closeout_date":20,"issuing_office":120,"recipient_name":131,"body_fetched_at":132,"delivery_method":133,"recipient_title":20,"reference_number":20,"action_taken_date":134,"medical_device_id":20,"response_letter_date":20},3260,[117,118,119,120,121,13,13,13],"\u003Ctime datetime=\"2021-07-13T13:20:00Z\">07\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-01T04:00:00Z\">07\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomedical-research-laboratories-llc-612831-07012021\">Biomedical Research Laboratories, LLC\u003C\u002Fa>","Office of Human and Animal Food Operations –West Division 5","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Christopher Jacob\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Biomedical Research Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7590 Fay Ave Suite 202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>La Jolla\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92037-4885\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations –West Division 5\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>July 1, 2021\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL 612831\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jacob:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fnativeorigins.com and https:\u002F\u002Fbrlsports.com in May 2021 and has determined that you take orders at https:\u002F\u002Fnativeorigins.com for your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products, and that you take orders at https:\u002F\u002Fbrlsports.com for your Flexify and Altitude RX products. We have also reviewed your website https:\u002F\u002Fbrlscience.com and your social media website at http:\u002F\u002Fwww.facebook.com\u002Fmynativeorigins, which direct consumers to your website https:\u002F\u002Fnativeorigins.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Calm Legs\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Calm Legs product page:\u003Cbr>\n&nbsp; o “Are you suffering with symptoms of Restless Legs Syndrome? . . . Calm Legs provides natural relief from the jumpy legs and fatigue associated with RLS.”\u003Cbr>\n&nbsp; o “For many users, Calm Legs brings rapid relief from Restless Legs Syndrome...”\u003Cbr>\n&nbsp; o “Calm Legs is the first natural supplement to address nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce its symptoms. Calm Legs is the only RLS natural supplement that contains the seven natural ingredients clinically proven to relieve RLS symptoms. To learn more, read our blog post, ‘How Do the Ingredients in Calm Legs Relax Restless Legs?’”\u003Cbr>\n&nbsp; o “Each ingredient in the Calm Legs formula has been clinically tested and shown to reduce symptoms of RLS.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Calm Legs Relax Restless Legs?”:\u003Cbr>\n&nbsp; o “Calm Legs was the first natural supplement to address recently discovered nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce symptoms of RLS.”\u003Cbr>\n&nbsp; o “Researchers have suggested that valerian [an ingredient in Calm Legs] is a safe herb for managing RLS without side effects.”\u003Cbr>\n&nbsp; o “Restless legs are linked to bad circulation and unhealthy blood vessels. Vitamin C [an ingredient in Calm Legs] is famous for promoting flexible, healthy blood vessels. Vitamin C also boosts iron absorption, ‘regenerates’ Vitamin E and enhances circulation to the legs and feet. Research has found that vitamin C supplementation brings significant reductions in Restless Legs (RLS) symptoms.”\u003Cbr>\n&nbsp; o “Vitamin E [an ingredient in Calm Legs] is an RLS symptom relief multitasker that promotes flexible arteries, boosts leg circulation, modulates inflammation and supports healthy nervous system function. Research has shown that vitamin E supplementation was associated with ‘prompt and gratifying relief’ of nighttime leg cramping.”\u003Cbr>\n• On the blog post “Hope for RLS Sufferers”:\u003Cbr>\n&nbsp; o “Here’s the real breakthrough: A specific combination of these natural compounds taken in precise ratios appears to unlock lasting RLS relief. This combination is found in Calm Legs.”\u003Cbr>\n&nbsp; o “Calm Legs combines seven different, clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market. Calm Legs is producing results that many RLS sufferers, including Susan Thompson, call life- changing. After taking Calm Legs for three months, Susan stated: ‘Calm Legs gave me my life back. I'm sleeping better than I have in years. I feel happy and energetic. My legs are no longer jumpy. And no weird side effects! I feel like myself again.’”\u003Cbr>\n• On the blog post “Top 5 Natural Therapies for Restless Legs”:\u003Cbr>\n&nbsp; o “Calm Legs restores these depleted nutrients, addressing multiple aspects of RLS to provide soothing relief.”\u003Cbr>\n• On the blog post “How Stress Impacts RLS”:\u003Cbr>\n&nbsp; o “Calm Legs also contains four other vitamins (vitamin C, vitamin E, folic acid, and vitamin B12) that have been clinically shown to . . . manage inflammation . . . and overall reduce symptoms of RLS . . . ”\u003Cbr>\n• On the blog post “What is Restless Legs Syndrome?”:\u003Cbr>\n&nbsp; o “RLS can lead to a number of consequences, none of them good, including depression, sadness, sleep deprivation, memory loss, stress and fatigue. Since its causes are likely multiple and largely unknown, and there is no known cure, the current approach is to treat the symptoms. Calm Legs is a safe, natural remedy that has helped thousands of people relax and get a good night’s sleep. Order Calm Legs today for rapid relief from RLS...”\u003Cbr>\nOn your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Calm Legs combines seven different clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market.”\u003Cbr>\n• An embedded YouTube video includes the following claims:\u003Cbr>\n&nbsp; o “CALM LEGS IS THE SOLUTION FOR RESTLESS LEGS!”\u003Cbr>\n&nbsp; o “The key a new supplement called Calm Legs that’s been featured on WebMD and in Prevention Magazine. Calm Legs helps RLS sufferers wake up refreshed and alert, experience deep restful sleep, and provides lasting relief from restless legs.”\u003C\u002Fp>\n\n\u003Cp>On the Native Origins Facebook page:\u003Cbr>\n• “You don’t have to endure the unpleasant side effect that sometimes accompany RLS drugs. #RLS #restlesslegs #nativeorigins #calmlegs” [from an August 6, 2019 post]\u003Cbr>\n• “Stress is a major trigger for RLS. Find out how you can manage both ailments with natural remedies. #rls @nativeorigins #calmlegs #stress #rlstriggers” [from a July 29, 2019 post]\u003C\u002Fp>\n\n\u003Cp>The above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\u003Cbr>\n• “Feel more relaxed throughout the day and get restless leg relief with Calm Legs. Soothe jumpy leg muscles with natural supplements for restless legs syndrome.”\u003Cbr>\n• “Try our supplements for restless leg syndrome and relive [sic] sensations of itching, tingling, crawling, and the urge to move legs. Learn about Calm Legs today!”\u003Cbr>\n• “Natural Remedy for RLS”\u003Cbr>\n• “Discover how the ingredients and vitamins in Calm Legs help reduce the symptoms of restless leg syndrome where other prescription drug therapies fall short.”\u003Cbr>\n• “Learn more about Calm Legs, a natural remedy for RLS that offers relief from jumpy-jerky legs, creepy crawly sensations, and random kicking.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Flexify\u003C\u002Fstrong>\u003Cbr>\nOn your websites https:\u002F\u002Fbrlsports.com and https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• \"What are early signs of arthritis? . . . Used consistently, Flexify will help alleviate painful joint stiffness, joint discomfort... If you are experiencing pain in your elbows, knees, hips, thumbs, shoulders or fingers, you can expect relief from aches and soreness...\"\u003Cbr>\n• “Boswellia [an ingredient in Flexify] has been clinically shown to significantly decrease joint pain and improve joint function within seven days of use.”\u003Cbr>\n• “Glucosamine, chondroitin, and MSM [ingredients in Flexify] are well-studied ingredients for...relief from arthritis.”\u003Cbr>\n• “Ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen when taken daily for hip and knee arthritis pain.”\u003Cbr>\n• “Turmeric [an ingredient in Flexify] reduces joint pain and swelling by blocking inflammatory cytokines and enzymes.”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the blog post “How Do the Ingredients in Flexify Help Relieve Pain and Nourish Joints?”:\u003Cbr>\n&nbsp; o “[G]lucosamine [an ingredient in Flexify] supplementation significantly reduced the symptoms of osteoarthritis in the lower limbs and delayed the structural progression of osteoarthritis.”\u003Cbr>\n&nbsp; o “Boswellia [an ingredient in Flexify] extracts can be an effective painkiller and have anti-inflammatory properties that may prevent the loss of cartilage. Research shows that boswellic acid can prevent the formation of leukotrienes in the body. Leukotrienes are molecules that have been identified as a cause of inflammation which may inhibit the autoimmune process.”\u003Cbr>\n&nbsp; o “Taken daily, ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen for hip and knee arthritis pain. Ginger has been shown to have anti-inflammatory properties similar to ibuprofen and COX-2 inhibitors (e.g., Celebrex). In a 2012 study, a specialized ginger extract was as effective in reducing inflammatory reactions in RA as steroids. Earlier studies showed that taking a certain extract four times daily reduced osteoarthritis pain in the knee after three months of treatment, and another taken twice daily worked about as well as ibuprofen taken three times daily for hip and knee OA pain.”\u003Cbr>\n• On the blog post “5 Ways to Prevent Osteoarthritis in Athletes”:\u003Cbr>\n&nbsp; o “Flexify Advanced Joint Support is used by athletes and others affected by arthritis... Each tablet contains seven clinically tested, natural ingredients that help build and maintain healthy joints and cartilage, slowing the progression of osteoarthritis or preventing it completely.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Collagen Peptides\u003C\u002Fstrong>\u003Cbr>\nOn your product website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Collagen Peptides product page:\u003Cbr>\n&nbsp; o “Some studies have suggested that collagen supplementation may help lower your risk for heart disease . . . by reducing arterial stiffness and boosting ‘good’ HDL cholesterol.”\u003Cbr>\n• On the blog post “What Are the Health Benefits of Collagen?”:\u003Cbr>\n&nbsp; o “Research suggests that collagen peptide supplementation may also be effective in reducing pain and inflammation associated with chronic conditions like osteoarthritis.”\u003Cbr>\n&nbsp; o “If you’re looking to relieve aches and pains from joint stiffness…Native Origins Collagen Peptides may be a good option to add to your daily routine.”\u003Cbr>\n• On the blog post “4 Ways to Add Collagen to Your Day”:\u003Cbr>\n&nbsp; o “A 2018 systematic review published in the British Journal of Sports Medicine, researchers found that collagen supplements provided short-term relief from osteoarthritis-associated pain.”\u003Cbr>\n• On the blog post “How Do Collagen Peptides Support Healthy Hair, Skin, Nails and Joints?”:\u003Cbr>\n&nbsp; o “The major type of collagen found in cartilage, collagen type II is frequently used in applications intended to help relieve pain from conditions like rheumatoid arthritis. . . . A 2015 study found that adding type II collagen from chicken [an ingredient in Collagen Peptides] to the diet of people with rheumatoid arthritis was effective in reducing pain, stiffness and swelling of joints.”\u003Cbr>\n• On the blog post “Collagen and Joint Health”:\u003Cbr>\n&nbsp; o “Some studies have shown that taking collagen supplements may help increase bone mineral density, protect joint cartilage, and even reduce joint pain associated with arthritis.”\u003Cbr>\n&nbsp; o “Collagen . . . may help reduce pain, stiffness and swelling of the joints”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Prohemia\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Prohemia product page:\u003Cbr>\n&nbsp; o “Prohemia helps support healthy blood levels in individuals suffering from symptoms associated with anemia.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Prohemia Fight Anemia-Related Fatigue and Improve Stamina?”:\u003Cbr>\n&nbsp; o “Prohemia contains several potent antioxidants to reduce inflammation . . .”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Prohemia, promotes red blood cell production, . . . promotes hemoglobin production, and improves energy level and stamina in individuals with anemia.”\u003Cbr>\n• The featured testimonial: “Mom had a stroke on Procrit. Since starting Prohemia she has not needed any more transfusions. Her hemoglobin went from 9.3 G\u002FdL to 11.8 g\u002FdL.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Altitude RX\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Altitude RX product page:\u003Cbr>\n&nbsp; o “The active components in Altitude RX have been demonstrated to increase oxygen levels and reduce symptoms of Acute Mountain Sickness.”\u003Cbr>\n&nbsp; o “Reduce the debilitating symptoms caused by high altitude and vertigo with Altitude RX”\u003Cbr>\n• On the blog post “How Do the Ingredients in Altitude RX Help Prevent Altitude Sickness?”:\u003Cbr>\n&nbsp; o “Our scientists used the most potent compounds available in amounts shown to prevent symptoms of Acute Mountain Sickness.”\u003Cbr>\n&nbsp; o “Science has demonstrated that Ginkgo biloba [an ingredient in Altitude RX] has a remarkable ability to increase blood flow throughout the body, enabling it to cope better with decreased atmospheric oxygen levels. Antioxidant properties in the leaf extract increase vasodilation and peripheral blood flow in the capillary vessels, as well as decreasing blood viscosity and helping to regulate cerebral energy metabolism.”\u003Cbr>\n&nbsp; o “Rhodiola [an ingredient in Altitude RX] also has been shown to reverse the effects of asthenia. It reduces fatigue, labored breathing, rapid heart rate, sluggishness . . .”\u003Cbr>\n&nbsp; o “ALA, Vitamin C and Vitamin E [ingredients in Altitude RX] work synergistically to protect cells from free radical damage.”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlsports.com:\u003Cbr>\n• “Altitude RX is a patent-pending formula of natural ingredients that takes a preventive approach to reducing AMS symptoms, including nausea, headache, fatigue, shortness of breath and insomnia.”\u003Cbr>\n• “Altitude RX is designed to safely and significantly increase oxygen levels at high altitude…”\u003Cbr>\n• “Ginkgo [an ingredient in Altitude RX] can help protect against altitude sickness through its ability to improve blood flow, and thus oxygen delivery to the brain.\"\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Altitude RX patent-pending formula of all-natural ingredients takes a preventive approach to reducing Acute Mountain Sickness (AMS) symptoms.”\u003Cbr>\n• “One of the active ingredients in Altitude RX promotes increased blood flow throughout the body and decreases blood viscosity — which offsets the negative effects of the low oxygen levels found at high altitude. Better blood flow at altitude delivers more oxygen to your brain, eliminating headaches — and delivering more oxygen to your muscles...”\u003Cbr>\n\u003Cbr>\nFrom a July 22, 2019 post on the Native Origins Facebook page: “Don’t let altitude sickness slow you down. #altituderx #altitudesickness”\u003C\u002Fp>\n\n\u003Cp>The above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\u003Cbr>\n• “Take Altitude RX for altitude sickness prevention…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Trimmunity\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Trimmunity product page:\u003Cbr>\n&nbsp; o “Contains antioxidants to help fight off free radicals, which can damage cells and impact immune health.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Trimmunity Help Improve Our Immune Defenses?”:\u003Cbr>\n&nbsp; o “[E]lderberry [an ingredient in Trimmunity] is most often used to alleviate seasonal illness and respiratory challenges.”\u003Cbr>\n&nbsp; o “Both human and animal studies have suggested that echinacea [an ingredient in Trimmunity] stimulates immune function and activates natural killer cells.”\u003Cbr>\n&nbsp; o “Vitamin D [an ingredient in Trimmunity] helps minimize inflammation. . .”\u003Cbr>\n&nbsp; o “Vitamin C [an ingredient in Trimmunity] supports the production and integrity of white blood cells, which help protect against infection.”\u003Cbr>\n&nbsp; o “Zinc [an ingredient in Trimmunity] . . . works by . . . reducing inflammation... zinc may help prevent dangerous, out-of-control inflammation that can result from haywire immune responses.”\u003C\u002Fp>\n\n\u003Cp>Your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Calm Legs, Collagen Peptides, and Flexify are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Calm Legs, Collagen Peptides, and Flexify fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n19701 Fairchild\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number 612831 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at elodie.tong-lin@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Christopher Jacob\n\nRecipient Title\n\nCEO\n\nBiomedical Research Laboratories, LLC\n\n7590 Fay Ave Suite 202\n\nLa Jolla, CA 92037-4885\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations –West Division 5\n\nUnited States\n\nWARNING LETTER\n\nJuly 1, 2021\n\nWL 612831\n\nDear Mr. Jacob:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fnativeorigins.com and https:\u002F\u002Fbrlsports.com in May 2021 and has determined that you take orders at https:\u002F\u002Fnativeorigins.com for your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products, and that you take orders at https:\u002F\u002Fbrlsports.com for your Flexify and Altitude RX products. We have also reviewed your website https:\u002F\u002Fbrlscience.com and your social media website at http:\u002F\u002Fwww.facebook.com\u002Fmynativeorigins, which direct consumers to your website https:\u002F\u002Fnativeorigins.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nCalm Legs\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Calm Legs product page:\n\no “Are you suffering with symptoms of Restless Legs Syndrome? . . . Calm Legs provides natural relief from the jumpy legs and fatigue associated with RLS.”\n\no “For many users, Calm Legs brings rapid relief from Restless Legs Syndrome...”\n\no “Calm Legs is the first natural supplement to address nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce its symptoms. Calm Legs is the only RLS natural supplement that contains the seven natural ingredients clinically proven to relieve RLS symptoms. To learn more, read our blog post, ‘How Do the Ingredients in Calm Legs Relax Restless Legs?’”\n\no “Each ingredient in the Calm Legs formula has been clinically tested and shown to reduce symptoms of RLS.”\n\n• On the blog post “How Do the Ingredients in Calm Legs Relax Restless Legs?”:\n\no “Calm Legs was the first natural supplement to address recently discovered nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce symptoms of RLS.”\n\no “Researchers have suggested that valerian [an ingredient in Calm Legs] is a safe herb for managing RLS without side effects.”\n\no “Restless legs are linked to bad circulation and unhealthy blood vessels. Vitamin C [an ingredient in Calm Legs] is famous for promoting flexible, healthy blood vessels. Vitamin C also boosts iron absorption, ‘regenerates’ Vitamin E and enhances circulation to the legs and feet. Research has found that vitamin C supplementation brings significant reductions in Restless Legs (RLS) symptoms.”\n\no “Vitamin E [an ingredient in Calm Legs] is an RLS symptom relief multitasker that promotes flexible arteries, boosts leg circulation, modulates inflammation and supports healthy nervous system function. Research has shown that vitamin E supplementation was associated with ‘prompt and gratifying relief’ of nighttime leg cramping.”\n\n• On the blog post “Hope for RLS Sufferers”:\n\no “Here’s the real breakthrough: A specific combination of these natural compounds taken in precise ratios appears to unlock lasting RLS relief. This combination is found in Calm Legs.”\n\no “Calm Legs combines seven different, clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market. Calm Legs is producing results that many RLS sufferers, including Susan Thompson, call life- changing. After taking Calm Legs for three months, Susan stated: ‘Calm Legs gave me my life back. I'm sleeping better than I have in years. I feel happy and energetic. My legs are no longer jumpy. And no weird side effects! I feel like myself again.’”\n\n• On the blog post “Top 5 Natural Therapies for Restless Legs”:\n\no “Calm Legs restores these depleted nutrients, addressing multiple aspects of RLS to provide soothing relief.”\n\n• On the blog post “How Stress Impacts RLS”:\n\no “Calm Legs also contains four other vitamins (vitamin C, vitamin E, folic acid, and vitamin B12) that have been clinically shown to . . . manage inflammation . . . and overall reduce symptoms of RLS . . . ”\n\n• On the blog post “What is Restless Legs Syndrome?”:\n\no “RLS can lead to a number of consequences, none of them good, including depression, sadness, sleep deprivation, memory loss, stress and fatigue. Since its causes are likely multiple and largely unknown, and there is no known cure, the current approach is to treat the symptoms. Calm Legs is a safe, natural remedy that has helped thousands of people relax and get a good night’s sleep. Order Calm Legs today for rapid relief from RLS...”\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Calm Legs combines seven different clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market.”\n\n• An embedded YouTube video includes the following claims:\n\no “CALM LEGS IS THE SOLUTION FOR RESTLESS LEGS!”\n\no “The key a new supplement called Calm Legs that’s been featured on WebMD and in Prevention Magazine. Calm Legs helps RLS sufferers wake up refreshed and alert, experience deep restful sleep, and provides lasting relief from restless legs.”\n\nOn the Native Origins Facebook page:\n\n• “You don’t have to endure the unpleasant side effect that sometimes accompany RLS drugs. #RLS #restlesslegs #nativeorigins #calmlegs” [from an August 6, 2019 post]\n\n• “Stress is a major trigger for RLS. Find out how you can manage both ailments with natural remedies. #rls @nativeorigins #calmlegs #stress #rlstriggers” [from a July 29, 2019 post]\n\nThe above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\n\n• “Feel more relaxed throughout the day and get restless leg relief with Calm Legs. Soothe jumpy leg muscles with natural supplements for restless legs syndrome.”\n\n• “Try our supplements for restless leg syndrome and relive [sic] sensations of itching, tingling, crawling, and the urge to move legs. Learn about Calm Legs today!”\n\n• “Natural Remedy for RLS”\n\n• “Discover how the ingredients and vitamins in Calm Legs help reduce the symptoms of restless leg syndrome where other prescription drug therapies fall short.”\n\n• “Learn more about Calm Legs, a natural remedy for RLS that offers relief from jumpy-jerky legs, creepy crawly sensations, and random kicking.”\n\nFlexify\n\nOn your websites https:\u002F\u002Fbrlsports.com and https:\u002F\u002Fnativeorigins.com:\n\n• \"What are early signs of arthritis? . . . Used consistently, Flexify will help alleviate painful joint stiffness, joint discomfort... If you are experiencing pain in your elbows, knees, hips, thumbs, shoulders or fingers, you can expect relief from aches and soreness...\"\n\n• “Boswellia [an ingredient in Flexify] has been clinically shown to significantly decrease joint pain and improve joint function within seven days of use.”\n\n• “Glucosamine, chondroitin, and MSM [ingredients in Flexify] are well-studied ingredients for...relief from arthritis.”\n\n• “Ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen when taken daily for hip and knee arthritis pain.”\n\n• “Turmeric [an ingredient in Flexify] reduces joint pain and swelling by blocking inflammatory cytokines and enzymes.”\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the blog post “How Do the Ingredients in Flexify Help Relieve Pain and Nourish Joints?”:\n\no “[G]lucosamine [an ingredient in Flexify] supplementation significantly reduced the symptoms of osteoarthritis in the lower limbs and delayed the structural progression of osteoarthritis.”\n\no “Boswellia [an ingredient in Flexify] extracts can be an effective painkiller and have anti-inflammatory properties that may prevent the loss of cartilage. Research shows that boswellic acid can prevent the formation of leukotrienes in the body. Leukotrienes are molecules that have been identified as a cause of inflammation which may inhibit the autoimmune process.”\n\no “Taken daily, ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen for hip and knee arthritis pain. Ginger has been shown to have anti-inflammatory properties similar to ibuprofen and COX-2 inhibitors (e.g., Celebrex). In a 2012 study, a specialized ginger extract was as effective in reducing inflammatory reactions in RA as steroids. Earlier studies showed that taking a certain extract four times daily reduced osteoarthritis pain in the knee after three months of treatment, and another taken twice daily worked about as well as ibuprofen taken three times daily for hip and knee OA pain.”\n\n• On the blog post “5 Ways to Prevent Osteoarthritis in Athletes”:\n\no “Flexify Advanced Joint Support is used by athletes and others affected by arthritis... Each tablet contains seven clinically tested, natural ingredients that help build and maintain healthy joints and cartilage, slowing the progression of osteoarthritis or preventing it completely.”\n\nCollagen Peptides\n\nOn your product website https:\u002F\u002Fnativeorigins.com:\n\n• On the Collagen Peptides product page:\n\no “Some studies have suggested that collagen supplementation may help lower your risk for heart disease . . . by reducing arterial stiffness and boosting ‘good’ HDL cholesterol.”\n\n• On the blog post “What Are the Health Benefits of Collagen?”:\n\no “Research suggests that collagen peptide supplementation may also be effective in reducing pain and inflammation associated with chronic conditions like osteoarthritis.”\n\no “If you’re looking to relieve aches and pains from joint stiffness…Native Origins Collagen Peptides may be a good option to add to your daily routine.”\n\n• On the blog post “4 Ways to Add Collagen to Your Day”:\n\no “A 2018 systematic review published in the British Journal of Sports Medicine, researchers found that collagen supplements provided short-term relief from osteoarthritis-associated pain.”\n\n• On the blog post “How Do Collagen Peptides Support Healthy Hair, Skin, Nails and Joints?”:\n\no “The major type of collagen found in cartilage, collagen type II is frequently used in applications intended to help relieve pain from conditions like rheumatoid arthritis. . . . A 2015 study found that adding type II collagen from chicken [an ingredient in Collagen Peptides] to the diet of people with rheumatoid arthritis was effective in reducing pain, stiffness and swelling of joints.”\n\n• On the blog post “Collagen and Joint Health”:\n\no “Some studies have shown that taking collagen supplements may help increase bone mineral density, protect joint cartilage, and even reduce joint pain associated with arthritis.”\n\no “Collagen . . . may help reduce pain, stiffness and swelling of the joints”\n\nProhemia\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Prohemia product page:\n\no “Prohemia helps support healthy blood levels in individuals suffering from symptoms associated with anemia.”\n\n• On the blog post “How Do the Ingredients in Prohemia Fight Anemia-Related Fatigue and Improve Stamina?”:\n\no “Prohemia contains several potent antioxidants to reduce inflammation . . .”\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Prohemia, promotes red blood cell production, . . . promotes hemoglobin production, and improves energy level and stamina in individuals with anemia.”\n\n• The featured testimonial: “Mom had a stroke on Procrit. Since starting Prohemia she has not needed any more transfusions. Her hemoglobin went from 9.3 G\u002FdL to 11.8 g\u002FdL.”\n\nAltitude RX\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Altitude RX product page:\n\no “The active components in Altitude RX have been demonstrated to increase oxygen levels and reduce symptoms of Acute Mountain Sickness.”\n\no “Reduce the debilitating symptoms caused by high altitude and vertigo with Altitude RX”\n\n• On the blog post “How Do the Ingredients in Altitude RX Help Prevent Altitude Sickness?”:\n\no “Our scientists used the most potent compounds available in amounts shown to prevent symptoms of Acute Mountain Sickness.”\n\no “Science has demonstrated that Ginkgo biloba [an ingredient in Altitude RX] has a remarkable ability to increase blood flow throughout the body, enabling it to cope better with decreased atmospheric oxygen levels. Antioxidant properties in the leaf extract increase vasodilation and peripheral blood flow in the capillary vessels, as well as decreasing blood viscosity and helping to regulate cerebral energy metabolism.”\n\no “Rhodiola [an ingredient in Altitude RX] also has been shown to reverse the effects of asthenia. It reduces fatigue, labored breathing, rapid heart rate, sluggishness . . .”\n\no “ALA, Vitamin C and Vitamin E [ingredients in Altitude RX] work synergistically to protect cells from free radical damage.”\n\nOn your website https:\u002F\u002Fbrlsports.com:\n\n• “Altitude RX is a patent-pending formula of natural ingredients that takes a preventive approach to reducing AMS symptoms, including nausea, headache, fatigue, shortness of breath and insomnia.”\n\n• “Altitude RX is designed to safely and significantly increase oxygen levels at high altitude…”\n\n• “Ginkgo [an ingredient in Altitude RX] can help protect against altitude sickness through its ability to improve blood flow, and thus oxygen delivery to the brain.\"\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Altitude RX patent-pending formula of all-natural ingredients takes a preventive approach to reducing Acute Mountain Sickness (AMS) symptoms.”\n\n• “One of the active ingredients in Altitude RX promotes increased blood flow throughout the body and decreases blood viscosity — which offsets the negative effects of the low oxygen levels found at high altitude. Better blood flow at altitude delivers more oxygen to your brain, eliminating headaches — and delivering more oxygen to your muscles...”\n\nFrom a July 22, 2019 post on the Native Origins Facebook page: “Don’t let altitude sickness slow you down. #altituderx #altitudesickness”\n\nThe above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\n\n• “Take Altitude RX for altitude sickness prevention…”\n\nTrimmunity\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Trimmunity product page:\n\no “Contains antioxidants to help fight off free radicals, which can damage cells and impact immune health.”\n\n• On the blog post “How Do the Ingredients in Trimmunity Help Improve Our Immune Defenses?”:\n\no “[E]lderberry [an ingredient in Trimmunity] is most often used to alleviate seasonal illness and respiratory challenges.”\n\no “Both human and animal studies have suggested that echinacea [an ingredient in Trimmunity] stimulates immune function and activates natural killer cells.”\n\no “Vitamin D [an ingredient in Trimmunity] helps minimize inflammation. . .”\n\no “Vitamin C [an ingredient in Trimmunity] supports the production and integrity of white blood cells, which help protect against infection.”\n\no “Zinc [an ingredient in Trimmunity] . . . works by . . . reducing inflammation... zinc may help prevent dangerous, out-of-control inflammation that can result from haywire immune responses.”\n\nYour Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Calm Legs, Collagen Peptides, and Flexify are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Calm Legs, Collagen Peptides, and Flexify fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n19701 Fairchild\n\nIrvine, CA 92612\n\nRefer to Unique Identification Number 612831 when replying.\n\nIf you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at elodie.tong-lin@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations –West Division 5","Biomedical Research Laboratories, LLC","biomedical-research-laboratories-llc-612831-07012021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomedical-research-laboratories-llc-612831-07012021","2026-10-26T08:08:05.137198+00:00","2021-07-13","612831","Food & Beverages","Mr. Christopher Jacob","2026-08-20T02:58:27.948+00:00","United Parcel Service","2021-07-01",{"id":136,"raw":137,"subject":141,"body_html":142,"body_text":143,"firm_name":144,"letter_id":145,"created_at":146,"fei_number":20,"letter_url":147,"updated_at":148,"action_type":23,"case_status":24,"posted_date":149,"marcs_cms_no":150,"product_type":151,"closeout_date":20,"issuing_office":11,"recipient_name":152,"body_fetched_at":153,"delivery_method":154,"recipient_title":20,"reference_number":20,"action_taken_date":155,"medical_device_id":20,"response_letter_date":20},21674,[138,139,140,11,141,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flovelace-biomedical-research-institute-725136-10062026\">Lovelace Biomedical Research Institute\u003C\u002Fa>","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert W. Rubin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lovelace Biomedical Research Institute\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2425 Ridgecrest Drive SE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Albuquerque\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 27-HFD-45-10-01\u003C\u002Fp>\u003Cp>Dear Mr. Rubin:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Lovelace Biomedical Research Institute (LBRI) between April 7 and 18, 2025. The investigator representing FDA reviewed the role of LBRI as the testing facility for the following nonclinical laboratory studies:\u003C\u002Fp>\u003Cul>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 9, 2025, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 9, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure of the quality assurance unit (QAU) to review the final study report to [en]sure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following observations found in the raw data were not documented in the final study report:\u003C\u002Fp>\u003Cp>1. For 20 out of 34 animals, the final study report did not include all the abnormal cageside clinical observations that were documented between October 1 and January 3, 2024, including but not limited to sneezing; runny or bloody nose; liquid, loose, mucoid, or semisolid stool; sunken eyes; swollen perineum; bloating; hunched posture; low appetite; and heavy breathing.\u003C\u002Fp>\u003Cp>2. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Intravenous Dosing and Blood Collection:\u003C\u002Fp>\u003Cp>a. Animal 3002, during dosing on October 16, 2023, laid on the cage bottom for one hour and ten minutes after infusion of the test article.\u003C\u002Fp>\u003Cp>b. Animals 3004 and 3005, during dosing on October 16, 2023, pulled out their venous catheters during infusion of the test article.\u003C\u002Fp>\u003Cp>c. Animals 1003 and 1004, during dosing on November 1, 2023, pulled out their venous catheters during infusion of the control article.\u003C\u002Fp>\u003Cp>d. Animal 4005, during dosing on November 11, 2023, had infiltration of the test article into the surrounding tissue of the left saphenous vein.\u003C\u002Fp>\u003Cp>Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following concerns and observations noted in the raw data were not documented in the final study report:\u003C\u002Fp>\u003Cp>3. The final study report did not include all the abnormal cageside clinical observations for all 48 animals, documented between November 21, 2022, and July 13, 2023, including incidences of abnormal stool observations, such as bloody or dark-red, liquid, loose, mucoid, or unformed stools.\u003C\u002Fp>\u003Cp>4. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Inhalation Exposure and PK Blood Collection:\u003C\u002Fp>\u003Cp>a. Animal 2006, during dosing on January 10, 2023, had irregular breathing from the aerosol dosing system during the last few minutes of dosing.\u003C\u002Fp>\u003Cp>b. Animal 5008, during dosing on April 2, 2023, had irregular breathing and was removed from the aerosol dosing system intermittently.\u003C\u002Fp>\u003Cp>c. Animal 2004, during dosing on April 5, 2023, had irregular breathing and was removed from the aerosol dosing system after the first 30 minutes of the dose exposure.\u003C\u002Fp>\u003Cp>d. Animal 3004, on June 14, 2023, was not dosed due to a swollen muzzle.\u003C\u002Fp>\u003Cp>We acknowledge that this finding as described above was not included on the Form FDA 483 you received, and therefore your written response did not directly address the violation as discussed in this letter.\u003C\u002Fp>\u003Cp>In your May 9, 2025, written response to the Form FDA 483, regarding the abnormal cageside clinical observations, you stated that documentation of the review of Animal Management System records would be added to the study file, and an addendum would be added to the final study reports for Protocols \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by May 31, 2025. You also stated that SOP-1106 (Preparation of a Final Report) and SOP-1882 (Animal Records and Animal Study Data Maintained at LBRI) would be updated by June 15, 2025. Regarding the individual dosing-related issues, your written response acknowledged that the final reports did not specifically discuss individual dosing issues. You stated that documentation of the review of those issues would be added to the study file and an addendum would be added to the final reports, as appropriate, by May 31, 2025. We acknowledge receipt of the revised final study reports, both of which were dated May 30, 2025.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. Specifically, you did not provide sufficient details regarding the updated SOPs, including the nature of the proposed or completed updates. Your corrective action plan also did not include any training on the updated SOPs or on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. In addition, the revised final study reports did not completely address the individual dosing issues. Finally, your corrective action plan did not include a description of any planned audits to check for compliance with updated procedures, as applicable. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Because the testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflected the raw data of the nonclinical laboratory studies, FDA is concerned about the integrity of the data generated and reported from nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>We emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, as well as any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>10\u002F06\u002F2026 10:05:58 AM\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert W. Rubin\n\nRecipient Title\n\nCEO\n\nLovelace Biomedical Research Institute\n\n2425 Ridgecrest Drive SE\n\nAlbuquerque, NM 87108\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 27-HFD-45-10-01\nDear Mr. Rubin:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Lovelace Biomedical Research Institute (LBRI) between April 7 and 18, 2025. The investigator representing FDA reviewed the role of LBRI as the testing facility for the following nonclinical laboratory studies:\nProtocol (b)(4): “(b)(4),” of the investigational drug (b)(4), performed for (b)(4)\nProtocol (b)(4): “(b)(4),” of the investigational drug (b)(4), performed for (b)(4)\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\nAt the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 9, 2025, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 9, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\nFailure of the quality assurance unit (QAU) to review the final study report to [en]sure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\nThe QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements.\nSpecifically, for Protocol (b)(4), the following observations found in the raw data were not documented in the final study report:\n1. For 20 out of 34 animals, the final study report did not include all the abnormal cageside clinical observations that were documented between October 1 and January 3, 2024, including but not limited to sneezing; runny or bloody nose; liquid, loose, mucoid, or semisolid stool; sunken eyes; swollen perineum; bloating; hunched posture; low appetite; and heavy breathing.\n2. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Intravenous Dosing and Blood Collection:\na. Animal 3002, during dosing on October 16, 2023, laid on the cage bottom for one hour and ten minutes after infusion of the test article.\nb. Animals 3004 and 3005, during dosing on October 16, 2023, pulled out their venous catheters during infusion of the test article.\nc. Animals 1003 and 1004, during dosing on November 1, 2023, pulled out their venous catheters during infusion of the control article.\nd. Animal 4005, during dosing on November 11, 2023, had infiltration of the test article into the surrounding tissue of the left saphenous vein.\nSpecifically, for Protocol (b)(4), the following concerns and observations noted in the raw data were not documented in the final study report:\n3. The final study report did not include all the abnormal cageside clinical observations for all 48 animals, documented between November 21, 2022, and July 13, 2023, including incidences of abnormal stool observations, such as bloody or dark-red, liquid, loose, mucoid, or unformed stools.\n4. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Inhalation Exposure and PK Blood Collection:\na. Animal 2006, during dosing on January 10, 2023, had irregular breathing from the aerosol dosing system during the last few minutes of dosing.\nb. Animal 5008, during dosing on April 2, 2023, had irregular breathing and was removed from the aerosol dosing system intermittently.\nc. Animal 2004, during dosing on April 5, 2023, had irregular breathing and was removed from the aerosol dosing system after the first 30 minutes of the dose exposure.\nd. Animal 3004, on June 14, 2023, was not dosed due to a swollen muzzle.\nWe acknowledge that this finding as described above was not included on the Form FDA 483 you received, and therefore your written response did not directly address the violation as discussed in this letter.\nIn your May 9, 2025, written response to the Form FDA 483, regarding the abnormal cageside clinical observations, you stated that documentation of the review of Animal Management System records would be added to the study file, and an addendum would be added to the final study reports for Protocols (b)(4) and (b)(4) by May 31, 2025. You also stated that SOP-1106 (Preparation of a Final Report) and SOP-1882 (Animal Records and Animal Study Data Maintained at LBRI) would be updated by June 15, 2025. Regarding the individual dosing-related issues, your written response acknowledged that the final reports did not specifically discuss individual dosing issues. You stated that documentation of the review of those issues would be added to the study file and an addendum would be added to the final reports, as appropriate, by May 31, 2025. We acknowledge receipt of the revised final study reports, both of which were dated May 30, 2025.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. Specifically, you did not provide sufficient details regarding the updated SOPs, including the nature of the proposed or completed updates. Your corrective action plan also did not include any training on the updated SOPs or on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. In addition, the revised final study reports did not completely address the individual dosing issues. Finally, your corrective action plan did not include a description of any planned audits to check for compliance with updated procedures, as applicable. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\nBecause the testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflected the raw data of the nonclinical laboratory studies, FDA is concerned about the integrity of the data generated and reported from nonclinical studies conducted at your testing facility.\nWe emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, as well as any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n10\u002F06\u002F2026 10:05:58 AM","Lovelace Biomedical Research Institute","lovelace-biomedical-research-institute-725136-10062026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flovelace-biomedical-research-institute-725136-10062026","2026-11-17T01:02:03.701861+00:00","2026-10-13","725136","Drugs","Robert W. Rubin","2026-10-14T12:32:02.221+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2026-10-06",7,{"510k":158,"classification":159,"enforcement":160,"event":161,"event_backfill":162,"pma":163,"warning_letter":164},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]